Document And Entity Information
Document And Entity Information | 12 Months Ended |
Dec. 31, 2018shares | |
Document Information [Line Items] | |
Entity Registrant Name | EDAP TMS SA |
Entity Central Index Key | 0001041934 |
Trading Symbol | edap |
Current Fiscal Year End Date | --12-31 |
Entity Filer Category | Accelerated Filer |
Entity Current Reporting Status | Yes |
Entity Voluntary Filers | No |
Entity Well-known Seasoned Issuer | No |
Entity Emerging Growth Company | false |
Entity Common Stock, Shares Outstanding (in shares) | 28,997,866 |
Document Type | 20-F |
Document Period End Date | Dec. 31, 2018 |
Document Fiscal Year Focus | 2018 |
Document Fiscal Period Focus | FY |
Amendment Flag | false |
Entity Shell Company | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Current assets | ||
Cash and cash equivalents | € 19,464 | € 20,004 |
Current portion of net trade accounts and notes receivable | 11,884 | 11,277 |
Other receivables | 1,434 | 1,066 |
Inventories | 7,212 | 6,739 |
Other assets, current portion | 382 | 489 |
Total current assets | 40,376 | 39,574 |
Non-current assets | ||
Property and equipment, net | 4,208 | 3,682 |
Intangible assets, net | 847 | 527 |
Goodwill | 2,412 | 2,412 |
Deposits and other non-current assets | 546 | 462 |
Deferred tax assets | 324 | 165 |
Net Trade accounts and notes receivable, non-current | 26 | 77 |
Total assets | 48,740 | 46,897 |
Current liabilities | ||
Trade accounts and notes payable | 6,297 | 6,310 |
Deferred revenues, current portion | 1,929 | 2,295 |
Social security and other payroll withholdings taxes | 1,177 | 1,075 |
Employee absences compensation | 612 | 575 |
Income taxes payable | 118 | 147 |
Other accrued liabilities | 2,122 | 1,536 |
Short-term borrowings | 3,683 | 2,718 |
Current portion of capital lease obligations | 383 | 255 |
Current portion of financial instruments carried at fair value | 840 | |
Current portion of long-term debt | 491 | 383 |
Total current liabilities | 16,812 | 16,134 |
Non-current liabilities | ||
Deferred revenues, non-current | 973 | 562 |
Capital lease obligations, non-current | 852 | 528 |
Financial instruments carried at fair value, non-current | ||
Long-term debt, non-current | 1,339 | 834 |
Other long-term liabilities | 3,800 | 3,681 |
Total liabilities | 23,776 | 21,739 |
Shareholders’ equity | ||
Common stock, €0.13 par value; 29,368,394 shares issued and 28,997,866 shares outstanding at December 31, 2018 and 2017, respectively | 3,818 | 3,818 |
Additional paid-in capital | 65,983 | 65,694 |
Retained earnings | (39,947) | (39,608) |
Cumulative other comprehensive loss | (3,748) | (3,604) |
Treasury stock, at cost; 370,528 at December 31, 2018 and at December 31, 2017 | (1,142) | (1,142) |
Total shareholders’ equity | 24,964 | 25,158 |
Total liabilities and shareholders’ equity | € 48,740 | € 46,897 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - € / shares | Dec. 31, 2018 | Dec. 31, 2017 |
Common stock, par value (in EUR per share) | € 0.13 | € 0.13 |
Common stock, shares issued (in shares) | 29,368,394 | 29,368,394 |
Common stock, shares outstanding (in shares) | 28,997,866 | 28,997,866 |
Treasury stock, shares (in shares) | 370,528 | 370,528 |
Consolidated Statements of Inco
Consolidated Statements of Income (Loss) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Revenues | € 39,183 | € 35,746 | € 35,611 |
Cost of sales | (22,266) | (20,938) | (19,200) |
Gross profit | 16,917 | 14,808 | 16,411 |
Research and development expenses | (4,088) | (3,881) | (3,868) |
Selling and marketing expenses | (10,551) | (9,526) | (8,856) |
General and administrative expenses | (3,593) | (3,428) | (3,296) |
Income (loss) from operations | (1,315) | (2,027) | 392 |
Financial income (expense), net | 797 | 2,643 | 3,949 |
Foreign Currency exchange (losses) gains, net | 538 | (909) | 103 |
Income (loss) before taxes | 20 | (293) | 4,444 |
Income tax (expense) credit | (358) | (388) | (602) |
Net income (loss) | € (338) | € (681) | € 3,842 |
Basic income (loss) per share (in EUR per share) | € (0.01) | € (0.02) | € 0.14 |
Diluted income (loss) per share (in EUR per share) | € (0.01) | € (0.02) | € 0.13 |
Basic Weighted average shares outstanding (in shares) | 28,997,866 | 28,961,928 | 27,823,313 |
Diluted Weighted average shares outstanding (in shares) | 28,997,866 | 28,961,928 | 29,365,583 |
Product [Member] | |||
Revenues | € 25,070 | € 22,580 | € 24,045 |
Cost of sales | (14,053) | (13,170) | (12,288) |
HIFU Treatments and Devices Leased [Member] | |||
Revenues | 5,086 | 5,095 | 4,906 |
Cost of sales | (2,557) | (2,667) | (2,527) |
Parts and Services [Member] | |||
Revenues | 9,007 | 8,011 | 6,628 |
Cost of sales | (5,655) | (5,101) | (4,385) |
Product and Services, Excluding Other [Member] | |||
Revenues | 39,163 | 35,686 | 35,579 |
Product and Service, Other [Member] | |||
Revenues | € 19 | € 60 | € 32 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income (Loss) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Net income (loss) | € (338) | € (681) | € 3,842 |
Other comprehensive income (loss): | |||
Foreign currency translation adjustments | (146) | 288 | (144) |
Provision for retirement indemnities | 57 | (238) | |
Comprehensive income (loss), net of tax | € (483) | € (336) | € 3,460 |
Consolidated Statements of Shar
Consolidated Statements of Shareholders' Equity - EUR (€) € in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Treasury Stock [Member] | Total |
Balance (in shares) at Dec. 31, 2015 | 25,383,461 | |||||
Balance at Dec. 31, 2015 | € 3,348 | € 58,560 | € (42,769) | € (3,567) | € (1,142) | € 14,430 |
Net income (loss) | 3,842 | 3,842 | ||||
Translation adjustment | (144) | (144) | ||||
Warrants and stock options granted or exercised | 360 | 360 | ||||
Capital increase (in shares) | 3,344,155 | |||||
Capital increase | € 435 | 5,765 | 6,200 | |||
Provision for retirement indemnities | (238) | (238) | ||||
Balance (in shares) at Dec. 31, 2016 | 28,727,616 | |||||
Balance at Dec. 31, 2016 | € 3,783 | 64,685 | (38,927) | (3,949) | (1,142) | 24,451 |
Net income (loss) | (681) | (681) | ||||
Translation adjustment | 288 | 288 | ||||
Warrants and stock options granted or exercised | 382 | 382 | ||||
Capital increase (in shares) | 270,250 | |||||
Capital increase | € 35 | 627 | 662 | |||
Provision for retirement indemnities | 57 | 57 | ||||
Balance (in shares) at Dec. 31, 2017 | 28,997,866 | |||||
Balance at Dec. 31, 2017 | € 3,818 | 65,694 | (39,608) | (3,604) | (1,142) | 25,158 |
Net income (loss) | (338) | (338) | ||||
Translation adjustment | (146) | (146) | ||||
Warrants and stock options granted or exercised | 289 | 289 | ||||
Provision for retirement indemnities | ||||||
Balance (in shares) at Dec. 31, 2018 | 28,997,866 | |||||
Balance at Dec. 31, 2018 | € 3,818 | € 65,983 | € (39,947) | € (3,748) | € (1,142) | € 24,964 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Cash flows from operating activities | |||
Net income (loss) | € (338) | € (681) | € 3,842 |
Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities: | |||
Depreciation and amortization | 1,610 | 1,573 | 1,025 |
Change in warrants fair value | (889) | (2,669) | (3,985) |
Other Non-cash compensation | 289 | 382 | 360 |
Change in allowances for doubtful accounts & slow-moving inventories | 591 | 28 | (75) |
Change in long-term provisions | 300 | 105 | 116 |
Net capital loss on disposals of assets | 37 | 47 | 58 |
Deferred tax expense (benefit) | (153) | (153) | 65 |
Operating cash flow | 1,447 | (1,368) | 1,408 |
Increase/Decrease in operating assets and liabilities: | |||
Decrease (Increase) in trade accounts and notes and other receivables | (983) | (1,741) | 1,752 |
Decrease (Increase) in inventories | (704) | 669 | (1,985) |
Decrease (Increase) in other assets | 115 | (47) | 46 |
(Decrease) Increase in trade accounts and notes payable | (70) | 426 | (153) |
(Decrease) Increase in accrued expenses, other current liabilities | 370 | (998) | 143 |
Net increase (decrease) in operating assets and liabilities | (1,272) | (1,691) | (197) |
Net cash generated by (used in) operating activities | 175 | (3,059) | 1,209 |
Cash flows from investing activities: | |||
Additions to capitalized assets produced by the Company | (827) | (988) | (853) |
Net proceeds from sale of leased back assets | 359 | 85 | |
Acquisitions of property and equipment | (604) | (631) | (321) |
Acquisitions of intangible assets | (438) | (453) | (151) |
Proceeds from sale of short term investments | 1,000 | ||
Increase in deposits and guarantees | (59) | (45) | (59) |
Net cash generated by (used in) investing activities | (1,569) | (2,032) | (384) |
Cash flow from financing activities: | |||
Proceeds from capital increase | 548 | 6,200 | |
Proceeds from stock-option exercise | 115 | ||
Proceeds from long term borrowings, net of financing costs | 1,032 | 1,638 | 3,168 |
Repayment of long term borrowings | (443) | (243) | (305) |
Repayment of obligations under capital leases | (358) | (297) | (277) |
Increase (decrease) in bank overdrafts and short-term borrowings | 946 | 1,110 | (1,182) |
Net cash generated by (used in) financing activities | 1,178 | 2,871 | 7,604 |
Net effect of exchange rate changes on cash and cash equivalents | (323) | 235 | (19) |
Net increase (decrease) in cash and cash equivalents | (539) | (1,985) | 8,410 |
Cash and cash equivalents at beginning of year | 20,004 | 21,989 | 13,578 |
Cash and cash equivalents at end of year | € 19,464 | € 20,004 | € 21,989 |
Note 1 - Summary of Significant
Note 1 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 1—SUMMARY 1 1 EDAP TMS S.A. and its subsidiaries (‘‘the Company’’) are engaged in the development, production, marketing, distribution and maintenance of a portfolio of minimally-invasive medical devices for the treatment of urological diseases. The Company currently produces innovative robotic devices for treating stones of the urinary tract and localized prostate cancer. We also derive revenues from the distribution of urodynamics products and urology lasers. Net sales consist primarily of direct sales to hospitals and clinics in France and Europe, export sales to third Moreover, the Company develops a novel HIFU treatment for liver cancer in cooperation with its long-term academic partner INSERM and leading cancer centers (the “HECAM” project). The Company purchases the majority of the components used in its products from a number of suppliers but for some components, relies on a single source. Delay would be caused if the supply of these components or other components was interrupted and these delays could be extended in certain situations where a component substitution may 1 2 These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). With the exception of the change in the Company’s Revenue Recognition Policy as a result of the adoption of ASC 606, no December 31, 2018, 1 3 The preparation of financial statements in conformity with U.S. generally accepted accounting principles (‘‘U.S. GAAP’’) requires management to make estimates and assumptions, such as business plans, stock price volatility, duration of standard warranty per market, price of maintenance contract used to determine the amount of revenue to be deferred and life duration of our range of products. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. 1 4 The accompanying consolidated financial statements include the accounts of EDAP TMS S.A. and all its domestic and foreign owned subsidiaries. 1 5 The Company adopted ASC Topic 606, Revenue from Contracts with Customers January 1, 2018. The Company’s revenue consists of: - Sales of goods (devices and consumables), where invoicing takes place upon delivery. - Revenue-per-Procedures (“RPP”) and leases: they comprise (i) revenues on a per treatment basis which are invoiced after each treatment, or in advance, or on a periodic basis, (ii) leases of devices, which are generally invoiced on a monthly or quarterly basis, and (iii) lease components arising from multiple-element arrangements, where specific sales terms are negotiated in accordance with each customer’s individual requirements and which are generally invoiced based on contract terms, - Sales of spare parts and services (maintenance, upgrades, mobility and others). Spare parts are invoiced when delivered. Regarding services, invoicing is performed either on a subscription basis (in advance or at the end of the period) or when performed. The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due between one three The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the goods or services and their payment terms can be identified, the contract has commercial substance, collectability of the contract consideration is probable, it is approved and the parties are committed to their obligations. Our sale arrangements may may not For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the goods or services. If a standalone selling price is not not The Company recognizes revenue when the performance obligations are satisfied by transferring control over the good or service to a customer. The Company’s revenue consists of the following: Sales of goods: Sales of goods are and have historically been comprised of net sales of medical devices (ESWL lithotripters and HIFU devices) and net sales of disposables (mostly Ablapaks and Focalpaks in the HIFU division and electrodes in the UDS division). Sales of goods also includes products such as urology laser and urodynamics devices distributed through our agents and third For devices and disposables, revenue is recognized when the Company transfers control to the customer (i.e. when the customer has the ability to direct the use of, and obtain substantially all of the remaining benefit from, the device or disposables), which is generally at the point of delivery or installation, depending on the terms of the arrangement (i.e. when the customer can use the good to provide services or sell or exchange the good), and based on contractual incoterms. The Company’s sales arrangements do not one two not Sales of RPPs and leases: Sales of RPP and leases include the revenues from the sale of treatment procedures and from the leasing of machines. We provide machines to clinics and hospitals for free for a limited period, rather than selling the devices. These hospitals and clinics perform treatments using the devices and usually pay us based on the number of individual treatments provided. Revenues related to the sale of treatments invoiced on a ‘‘Revenue-Per-Procedure’’ (‘‘RPP’’) basis are recognized when the treatment procedure has been completed. Revenues from devices leased to customers under operating leases are recognized on a straight-line basis. Regarding multiple-element arrangements with a lease component, a portion of the contract is allocated to the lease component on the basis of observable market prices applied by the Company for similar devices under operating leases. The lease component is recognized on a straight line basis over the contractual period. Other components under the contract are recognized in accordance with their nature. Sales of spare parts and services: Revenues related to spare parts are recognized when spare parts are delivered to distributors who perform their own maintenance services. Spare parts used in the performance of EDAP’s own maintenance and repair services are generally not Revenues related to Services mainly consist of maintenance contracts which rarely exceed one no not The Company recognizes revenue for extended warranties included in the multiple-element arrangements as a separate performance obligation in Sales of services on a straight-line basis over the extended warranty period. In the majority of countries in which the Company operates, the statutory warranty period is one two not Agents and distributors: As part of its sale process in countries other than continental France, when the Company does not Deferred revenue: Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed, and consists primarily of billing or cash receipts in advance of services due under maintenance contracts or extended warranty contracts. The associated deferred revenue is generally recognized ratably over the service period. Disaggregation of revenue: Disaggregation by primary geographical market, and timing of revenue recognition is reported in Note 17. Contract Balances: Details on contract liabilities are reported on Note 10. The Company applies the practical expedient in paragraph 606 10 50 14 not one 1 6 Costs of sales include all direct product costs, costs related to shipping, handling, duties and importation fees, as well as certain indirect costs such as service and supply chain departments expenses. Indirect costs are allocated by type of sales (goods, RPP and leases, spare parts and services) using an allocation method determined by management by type of costs and segment activities and reviewed on an annual basis. 1 7 Shipping and handling costs are not 1 8 Cash equivalents are cash investments which are highly liquid and have initial maturities of 90 Cash investments with a maturity higher than 90 1 9 Accounts receivables are stated at cost net of allowances for doubtful accounts. The Company makes judgments as to its ability to collect outstanding receivables and provides allowances for the portion of receivables when collection becomes doubtful. Provision is made based upon a specific review of all significant outstanding invoices. These estimates are based on our bad debt write-off experience, analysis of credit information, specific identification of probable bad debt based on our collection efforts, aging of accounts receivables and other known factors. Accounts receivable also include factored receivables for which the Company is bearing the collection risk. 1 10 Inventories are valued at the lower of cost and net realizable value. Cost is either the manufacturing cost, which is principally comprised of components and labor costs for our own manufactured products, or purchase price for urology products we distribute. Cost is determined on a first first first 1 11 Property and equipment is stated at historical cost. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful life of the related assets, as follows: Leasehold improvements (in years) 10 or lease term if shorter Equipment (in years) 3 - 10 Furniture, fixtures, fittings and other (in years) 2 - 10 Equipment includes industrial equipment and research equipment that has alternative future uses. Equipment also includes devices that are manufactured by the Company and leased to customers through operating leases related to Revenue-Per-Procedure transactions and devices subject to sale and leaseback transactions. This equipment is depreciated over a period of seven 1 12 The Company reviews the carrying value of its long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not not 1 13 Goodwill represents the excess of purchase price over the fair value of identifiable net assets of businesses acquired. Goodwill is not 350, two first second second Changes in market conditions could have a major impact on the valuation of these assets and could result in additional impairment losses. Intangible assets consist primarily of purchased patents relating to lithotripters, purchased licenses, a purchased trade name and a purchased trademark. The basis for valuation of these assets is their historical acquisition cost. Amortization of intangible assets is calculated by the straight-line method over the shorter of the contractual or estimated useful life of the assets, as follows: Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7 1 14 Treasury stock purchases are accounted for at cost. The sale of treasury stocks is accounted for using the first first not 10% 1 15 The Company provides customers with a warranty for each product sold and accrues warranty expense at time of sale based upon historical claims experience. Standard warranty period may 1 2 €433 €316 €319 December 31, 2018, 2017 2016, 1 16 The Company accounts for income taxes in accordance with ASC 740, 740, not not ASC740, no Under ASC740, not 1 17 Research and development costs are recorded as an expense in the period in which they are incurred. The French government provides tax credits to companies for innovative research and development. This tax credit is calculated based on a percentage of eligible research and development costs and it can be refundable in cash and is not 1 18 Advertising costs are recorded as an expense in the period in which they are incurred and are included in selling and administrative expenses in the accompanying consolidated statements of income (loss). Advertising costs amounted to €719 €672 €744 December 31, 2018, 2017 2016, 1 19 Translation of the financial statements of consolidated companies The reporting currency of EDAP TMS S.A. for all years presented is the euro (€). The functional currency of each subsidiary is its local currency. In accordance with ASC 830, · · · · Foreign currencies transactions Transactions involving foreign currencies are translated into the functional currency using the exchange rate prevailing at the time of the transactions. Receivables and payables denominated in foreign currencies are translated at year-end exchange rates. The resulting unrealized exchange gains and losses are carried to the statement of income. Presentation in the Statement of Income Aggregate foreign currency transactions gains and losses are disclosed in a single caption in the Statement of Income under section “Foreign currency exchange gain (loss), net”. 1 20 Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted earnings per share reflects potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. The dilutive effects of the Company’s common stock options and warrants is determined using the treasury stock method to measure the number of shares that are assumed to have been repurchased using the average market price during the period, which is converted from U.S. dollars at the average exchange rate for the period. 1 21 ASC 815 Gains and losses from derivative instruments are recorded in the Statement of Income. 1 22 At December 31, 2018, four 718 1 23 The Company recorded outstanding warrants issued in March 2012, May 2013 April 2016 815 40 15 7 not December 31, 2018, no 1 24 In accordance with ASC 840, one - Ownership is transferred to the lessee by the end of the lease term; - The lease contains a bargain purchase option; - The lease term is at least 75% - The present value of the minimum lease payments at the beginning of the lease term is 90% For sales type leases, the following two - Collectability of the minimum lease payment is reasonably predictable; - No The Company enters into sale and leaseback transactions from time to time. In accordance with ASC 840, 1 25 Recently Adopted Accounting Pronouncements In July 2015, 2015 14 2015 14 No. 2014 09, Revenue from Contracts with Customers 606 one 606supersedes 605 The Company adopted Topic 606 Revenue from Contracts with Customers January 1, 2018. The Company applied Topic 606 using the cumulative effect method i.e. by recognizing the cumulative effect of initially applying Topic 606 January 1, 2018. not 605. In implementing Topic 606, December 31, 2018 2017. 606, not The impact to the Company of adopting the new revenue standard primarily relates to additional and expanded disclosures, and in particular contract liabilities and disaggregated revenues. There is no 2018 In November 2015, No. 2015 17, Balance Sheet Classification of Deferred Taxes 2015 17 2015 17 first 2017. 2015 17 December 31, 2017. In March 2016, 2016 09, 2016 09 2016 09 15 December 2016, No 2016 09. Recent Accounting Pronouncements Not In February 2016, No. 2016 02, 2016 02 840 842 12 December 15, 2018 January 1, 2019. not January 1, 2019, 2.9 In January 2017, 2017 04, 2 not first 2020. January 1, 2017. |
Note 2 - Cash Equivalents
Note 2 - Cash Equivalents | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Cash and Cash Equivalents Disclosure [Text Block] | 2—CASH Cash and cash equivalents and short-term investments are comprised of the following: December 31, 2018 2017 Total cash and cash equivalents 19.464 20,004 Short term investments – – Total cash and cash equivalents, and short term investments 19,464 20,004 |
Note 3 - Trade Accounts and Not
Note 3 - Trade Accounts and Notes Receivable, Net | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Loans, Notes, Trade and Other Receivables Disclosure [Text Block] | 3—TRADE Trade accounts and notes receivable consist of the following: December 31, 2018 2017 Trade accounts receivable 12,907 12,202 Notes receivable 408 181 Less: allowance for doubtful accounts (1,405 ) (1,029 ) Total 11,910 11,354 Less current portion (11,884 ) (11,277 ) Total long-term portion 26 77 Notes receivable usually represent commercial bills of exchange (drafts) with initial maturities of 90 Bad debt expenses amount to a cost of €362 €107 €18 December 31, 2018, 2017 2016. Long term portion consists of sales type leases of medical devices. Future minimum payments to be received over the five Sales type 2019 42 2020 18 2021 8 2022 – 2022 – Total minimum payments 70 |
Note 4 - Other Receivables
Note 4 - Other Receivables | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Other Receivables [Text Block] | 4—OTHER Other receivables consist of the following: December 31, 2018 2017 Research and development tax credit receivable from the French State 685 560 Value-added taxes receivable 390 216 Other receivables from Government and public authorities 233 238 Others 126 52 Total 1,434 1,066 |
Note 5 - Inventories
Note 5 - Inventories | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | 5—INVENTORIES Inventories consist of the following: December 31, 2018 2017 Components, spare parts 3,496 3,909 Work-in-progress 576 729 Finished goods – own manufactured products 2,672 1,167 Finished goods – distribution products 1,442 1,656 Total gross inventories 8,186 7,461 Less: allowance for slow-moving inventory and net realizable value (974 ) (722 ) Total 7,212 6,739 The provision for slow moving inventory relates to components and spare parts. The allowance for slow moving inventory (excluding exchange rate impact), the changes in which are classified within cost of sales, amounted to a cost of €227 December 31, 2018, €41 December 31, 2017, €55 December 31, 2016, |
Note 6 - Other Assets
Note 6 - Other Assets | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Other Assets Disclosure [Text Block] | 6—OTHER Other assets consist of the following: December 31, 2018 2017 Prepaid expenses, current portion 382 489 Total 382 489 Prepaid expenses mainly consist of rental and future congresses expenses. |
Note 7 - Property and Equipment
Note 7 - Property and Equipment, Net | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 7—PROPERTY Property and equipment consist of the following: December 31, 2018 2017 Equipment 8,677 7,588 Furniture, fixture, and fittings and other 4,064 3,766 Total gross value 12,742 11,354 Less: accumulated depreciation and amortization (8,534 ) (7,672 ) Total 4,208 3,682 Depreciation expense related to property and equipment amounted to €1,367 €1,153 €843 December 31, 2018, 2017 2016, Assets under capital leases: Capitalized costs on equipment held under capital leases of €2,704 €2,081 December 31, 2018 2017, €2,291 €2,018 December 31, 2018 2017, Capitalized costs on vehicles and office and IT equipment held under capital leases of €1,423 €981 December 31, 2018 2017, €619 €528 December 31, 2018 2017, Depreciation expense on assets held under capital leases is included in total depreciation expense and amounted to €386 €218 €164 December 31, 2018, 2017 2016, Assets leased to customers: Capitalized costs on equipment leased to customers of €351 €474 December 31, 2018 2017, third €72 €27 December 31, 2018 2017, Depreciation expense on equipment leased to customer is included in total depreciation expense and amounted to €51 €24 €2 December 31, 2018, 2017 2016, |
Note 8 - Goodwill and Intangibl
Note 8 - Goodwill and Intangible Assets | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | 8—GOODWILL As discussed in Note 1 13, 350 not 280 €1,767 €645 December 31, 2018. The Company completed the required annual impairment test in the fourth 2018. two no Intangible assets consist of the following: December 31, 2018 2017 Licenses 1,431 993 Trade name and trademark 414 393 Patents 412 412 Organization costs 320 320 Total gross value 2,577 2,118 Accumulated amortization for licenses (587 ) (477 ) Accumulated amortization for trade name and trademark (411 ) (383 ) Accumulated amortization for patents (412 ) (411 ) Accumulated amortization for organization costs (320 ) (320 ) Less: Total accumulated amortization (1,730 ) (1,591 ) Total 847 527 Licenses increase is mainly due to SAP program implementation. Amortization expenses related to intangible assets amounted to €110 €74 €42 December 31, 2018, 2017 2016, For the five December 31, 2019 97 2020 89 2021 87 2022 85 2023 83 Total 441 |
Note 9 - Trade Accounts and Not
Note 9 - Trade Accounts and Notes Payable | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 9—TRADE Trade accounts and notes payable consist of the following: December 31, 2018 2017 Trade accounts payable 6,286 6,220 Notes payable 11 90 Total 6,297 6,310 Trade accounts payable usually represent invoices with a due date of 90 Notes payable represent commercial bills of exchange (drafts) with initial maturities of 90 |
Note 10 - Deferred Revenues
Note 10 - Deferred Revenues | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Liability from Contract with Customer [Text Block] | 10—DEFERRED Deferred revenues consist of the following: December 31, 2018 2017 Deferred revenues on maintenance contracts 1,246 1,497 Deferred revenue on RPP 339 405 Deferred revenue on sale of devices 289 218 Deferred revenue on extension of warranty, included in sales contracts 855 676 Deferred research and development grants 173 61 Total 2,902 2,857 Less long term portion (973 ) (562 ) Current portion 1,929 2,295 Deferred revenue on extension of warranty will be recognized over the following periods: December 31, 2019 167 2020 264 2021 218 2022 162 2023 44 Total 855 The components of deferred revenue on extension of warranty for year ended December 31, 2018 Total Beginning balance 676 New extension of warranty 331 Recognition of revenue (152 ) Ending balance 855 |
Note 11 - Other Accrued Liabili
Note 11 - Other Accrued Liabilities | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Other Liabilities Disclosure [Text Block] | 11—OTHER Other accrued liabilities consist of the following: December 31, 2018 2017 Retirement indemnities 2,287 2,076 Provision for warranty costs 547 449 Accruals for payroll and associated taxes 680 611 Conditional government advances 1,039 1,039 Value added tax payable 327 125 Advances received from customers 115 108 Provision for Asset Retirement Obligation (Japan) 118 100 Provision for employee termination indemnities (Italy) 369 349 Provision for employee termination indemnities (Korea) 30 – Others 411 360 Total 5,923 5,217 Less non-current portion (3,800 ) (3,681 ) Current portion 2,122 1,536 We receive government conditional advances and grants for advanced research programs we conduct alone or in connection with other unrelated entities (mainly HECAM project) which are provided for and managed by French state-owned entities, and specifically “Banque Publique d’Investissement” (“Bpifrance”). We, alone or with other unrelated entities, enter into multi-year contractual arrangements for the financing of specific research programs. These arrangements consist of both grants and conditional advances which are paid in fixed instalments at predetermined contractual dates, subject generally to milestones based on progress of the research and documentation. Grants received are non-refundable. Conditional advances received are subject to a fixed 1.44% may 20 Conditional advances as of December 31, 2018, 2019 – 2020 – 2021 – 2022 203 2023 and thereafter 836 Total 1,039 Changes in the provision for warranty costs are as follows: December 31, 2018 2017 Beginning of year 449 548 Amount used during the year (335 ) (415 ) New warranty expenses 433 316 End of year 547 449 Less current portion (356 ) (265 ) Long term portion 191 184 |
Note 12 - Lease Obligations
Note 12 - Lease Obligations | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Leases of Lessee Disclosure [Text Block] | 12—LEASE 12 1 The Company leases certain of its equipment under capital leases. At December 31, 2018, €432 €802 December 31, 2018 December 31, 2019 401 2020 361 2021 252 2022 170 2023 and thereafter 89 Total minimum lease payments 1273 Less: amount representing interest (39 ) Present value of minimum lease payments 1,234 Less: current portion (383 ) Long-term portion 852 Interest paid under capital lease obligations was €21 €13 €18 December 31, 2018, 2017 2016, 12 2 As of December 31, 2018, one one one July 1, 2015 ten June 30, 2025, nine Future minimum lease payments for these operating leases consist of the following amounts: France Japan USA Italy 2019 329 227 45 37 2020 329 167 45 37 2021 329 132 4 37 2022 329 39 – 25 2023 and thereafter 822 – – – Total 2,138 565 94 135 Total rent expenses under operating leases amounted to €1,002 €904 €841 December 31, 2018, 2017 2016, |
Note 13 - Short-term Borrowings
Note 13 - Short-term Borrowings | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Short-term Debt [Text Block] | 13—SHORT As of December 31, 2018, €3,683 December 31, 2017, €2,718 |
Note 14 - Long Term Debt and Fi
Note 14 - Long Term Debt and Financial Instruments Carried at Fair Value | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | 14—LONG 14 1 December 31, 2018 2017 France term loan 526 700 Japanese term loan (YEN) 628 40 Germany term loan 632 399 Italy term loan 27 78 Malaysia term loan 17 – Total long term debt 1,830 1,217 Less current portion (491 ) (383 ) Total long-term portion 1,339 834 As of December 31, 2018, Initial Maturity Fixed Interest rate Frequency of EDAP Technomed Co. Ltd 80,000,000 November 30, 2025 1.98 % Monthly instalment As of December 31, 2017, two Initial Maturity Fixed Interest rate Frequency of EDAP Technomed Co. Ltd 55,000,000 June 30, 2018 1.80 % Monthly instalment 10,000,000 June 30, 2018 2.10 % Monthly instalment As of December 31, 2018 2017, two Initial Maturity Fixed Interest rate Frequency of EDAP TMS GMBH 450,000 November 30, 2020 2.49 % Monthly instalment This loan is pledged by an HIFU equipment with a purchase value of €450 Initial Maturity Fixed Interest rate Frequency of EDAP TMS GMBH 136,500 December 31, 2022 2.25 % Monthly instalment This loan is pledged by an UDS equipment with a purchase value of €136 And a new loan as of December 31, 2018 Initial Maturity Fixed Interest rate Frequency of EDAP TMS GMBH 400,000 April 30, 2023 2.40 % Monthly instalment This loan is pledged by an HIFU equipment with a purchase value of €438 As of December 31, 2018 2017, €242 1 4.5% June 6, 2019. As of December 31, 2018 2017, one Initial Maturity Fixed Interest rate Frequency of EDAP TMS FRANCE 700,000 October 16, 2021 0.40 % Quarterly instalment As of December 31, 2018, Initial Maturity Fixed Interest rate Frequency of EDAP TECHNOMED SDN BHD 90,000 July 31, 2022 4.64 % Monthly instalment 14 2 December 31, 2018 2017 Investor Warrants – 840 – Total – 840 Less current portion – (840 ) Total long-term portion – – On March 28, 2012, March 22, 2012, “March 2012 “March 2012 1,406,250 “March 2012 168,750 March 2012 “March 2012 March 2012 March 2012 On May 28, 2013, May 20, 2013, 3,000,000 “May 2013 $4.00 “May 2013 May 2013 1,500,000 $4.25. May 2013 November 29, 2013 November 29, 2018. $5.00 “May 2013 May 2013 “May 2013 May 2013 November 29, 2013 May 28, 2016. May 2013 March 2012 May 2013 May 2013 $12 9.270 $3.817 €2.950 $8.183 €6.320 16 1 May 2013 On April 14, 2016, April 7, 2016, 3,283,284 “April 2016 $3.50 “April 2016 April 2016 3,283,284 $4.50. April 2016 October 14, 2016 October 14, 2018. April 2016 March 2012 May 2013 April 2016 $11.5 10.2 $3.578 €3.168 $7.913 €7.006 16 1 April 2016 Fair Value of the May 2013 The valuation model of the Investor Warrants uses the following main assumptions and parameters based on a Black-Scholes model. Note that Warrant’s maturity is assumed to be their legal duration as per Warrant contract. At inception December 31, December 31, Share price at closing date $3.96 – $2.87 Strike price of warrants $4.25 – $4.25 Risk free interest rate at 5.5 years 1.07% – 0% Share price volatility 71% – 57.40% Dividend rates 0% – 0% Unit fair value $2.35 – $0.26 Total fair value (in thousand $) $3,525 – $392 Total equivalent amount (in thousand €) €2,725 – €328 As of December 31, 2018, May 2013 Fair Value of the April 2016 The valuation model of the Investor Warrants uses the following main assumptions and parameters based on a Black-Scholes model. Note that Warrant’s maturity is assumed to be their legal duration as per Warrant contract. At inception December 31, December 31, Share price at closing date 3.64 – 2.87 Strike price of warrants $4.50 – $4.50 Risk free interest rate at 2.5 years 0% – 0% Share price volatility 60.20% – 57.40% Dividend rates 0% – 0% Unit fair value $1.09 – $0.19 Total fair value (in thousand $) $3,579 – $614 Total equivalent amount (in thousands €) €3,168 – €512 As of December 31, 2018, April 2016 Refer to Note 24 14 3 Long-term debt and financial instruments carried at fair value at December 31, 2018 2019 491 2020 460 2021 381 2022 205 2023 and thereafter 293 Total 1,830 |
Note 15 - Other Long-term Liabi
Note 15 - Other Long-term Liabilities | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Other Long-term Liabilities, Disclosure [Text Block] | 15—OTHER Other long-term liabilities consist of the following: December 31, 2018 2017 Provision for retirement indemnities (Japan & France), less current portion 2,222 2,008 Provision for employee termination indemnities (Italy) less current portion 170 349 Provision for employee termination indemnities (Korea) less current portion 30 – Provision for Asset Retirement Obligation (Japan) less current portion 118 101 Provision for warranty costs, less current portion 191 184 Conditional government advances, less current portion 1,039 1,039 Accrued interest less current portion 30 – Total 3,800 3,68 1 Provision for asset retirement obligation in Japan is related to subsidiary’s offices and warehouses. Pension, post-retirement and post-employment benefits for most of the Company’s employees are sponsored by European governments. In addition to government-sponsored plans, subsidiaries in Japan and France have defined benefit retirement indemnity plans in place. The provision for retirement indemnities at December 31, 2018 The provision is management best estimate based on the following assumptions as of year-end: Pension Benefits - France 2018 2017 Discount rate 1.60 % 1.60 % Salary increase 2.50 % 2.50 % Retirement age 65 65 Average retirement remaining service period 24 24 Pension Benefits - Japan 2018 2017 Discount rate 0.50 % 0.50 % Salary increase 2.50 % 2.50 % Retirement age 60 60 Average retirement remaining service period 14 14 The discount rate retained is determined by reference to the high quality rates for AA- rated corporate bonds for a duration equivalent to that of the obligations. It derives from a benchmark per monetary area of different market data at the closing date. In 2018, 715 France Japan Non-current liabilities 966 1,255 Current liabilities 10 55 Accumulated other comprehensive income (loss) (161 ) (416 ) Total 815 895 In 2017, 715 France Japan Non-current liabilities 867 1,141 Current liabilities 27 40 Accumulated other comprehensive income (loss) (165 ) (412 ) Total 729 769 The Company does not three December 31, 2018: France 2018 2017 2016 Change in benefit obligations: Benefit obligations at beginning of year 895 842 694 Service cost 67 66 45 Interest cost 14 13 15 Actuarial (gain) / loss – – 88 Amortization of net prior service cost 1 1 – Benefits paid – (27 ) – Benefit obligations at end of year (1) 976 895 842 Unrecognized actuarial (gain) loss (2) 141 144 147 Unrecognized prior service cost (2) 20 22 23 Accrued pension cost 815 729 672 ( 1 The accumulated benefit obligation was €692 €627 December 31, 2018 2017 ( 2 The amount in accumulated other comprehensive income (loss) to be recognised as components of net periodic benefit costs in 2019 €4 Japan 2018 2017 2016 Change in benefit obligations: Benefit obligations at beginning of year 1,182 1,162 906 Service cost 131 118 81 Interest cost 6 6 10 Amortization of net loss 26 24 16 Actuarial (gain) / loss – (12 ) 147 Benefits paid (94 ) (17 ) (38 ) Exchange rate impact (60 ) (99 ) 40 Benefit obligations at end of year (1) 1,311 1,182 1,162 Unrecognized actuarial (gain) loss (2) 416 412 464 Unrecognized prior service cost (2) – – – Accrued pension cost 895 769 698 ( 1 The accumulated benefit obligation was €960 €872 December 31, 2018 2017, ( 2 The amount in accumulated other comprehensive income (loss) to be recognised as components of net periodic benefit costs in 2019 €26 The benefits expected to be paid in each of the next five five France Japan 2019 10 55 2020 – 6 2021 86 55 2022 – 75 2023 107 96 2024-2028 277 743 |
Note 16 - Shareholders' Equity
Note 16 - Shareholders' Equity | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 16—SHAREHOLDERS’ 16 1 As of December 31, 2018, 29,368,394 €0.13 28,997,866 16 2 Shareholders have preemptive rights to subscribe on a pro rata may not 16 3 Dividends may not €15,011 no 16 4 As of December 31, 2018, 370,528 190,238 August December 1998 €649 180,290 June July 2001 €493 370,528 16 5 16 5 As of December 31, 2018, 370,528 120,100 may €2.38 June 25, 2010. As of December 31, 2018, four On May 22, 2007, 600,000 600,000 Conforming to this stock option plan, on June 25, 2010, 95,912 €1.88 one June 25, 2014 ( four four June 25, 2020 ( ten no 2016, 2017 2018 718. 50,000 December 31, 2018. On June 24, 2010, 229,100 may June 25, 2010, 229,100 €2.38 one June 25, 2014 ( four four June 25, 2020 ( ten no 2016, 2017 2018 718. 120,100 December 31, 2018. On December 19, 2012, 500,000 500,000 500,000 January 18, 2013. €1.91 one January 18, 2017 ( four four January 18, 2023 ( ten December 31, 2013 €660 48 718, €29 €2 €0 2016, 2017 2018, 297,500 December 31, 2018. On February 18, 2016, 1,000,000 1,000,000 575,000 April 26, 2016. €3.22 one April 26, 2020 ( four four April 26, 2026 ( ten December 31, 2016 €960 48 Conforming to this February 18, 2016 260,000 April 25, 2017. €2.39 one April 25, 2021 ( four four April 25, 2027 ( ten December 31, 2017, April 25, 2017 €335 48 Conforming to this February 18, 2016 165,000 August 29, 2018. €2.65 one August 29, 2022 ( four four August 29, 2029 ( ten December 31, 2018, August 29, 2018 €219 48 The impact on operating income, in accordance with ASC 718, €331 €380 €289 2016, 2017 2018, Under this 2016 880,000 305,000 December 31, 2018. Forfeited stock-options are recognized as they occur, in accordance with ASU 2016 09. The fair value of each stock option granted during the year is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: Year Ended December 31, 2018 2017 2016 Weighted-average expected life (years) 6.25 6.25 6.25 Expected volatility rates (1) 52.6 % 57.4 % 60.60 % Expected dividend yield 0 % 0 % 0 % Risk-free interest rate 0.18 % 0.02 % 0.01 % Weighted-average exercise price (€) 2.65 2.39 3.22 Weighted-average fair value of options granted during the year (€) 1.33 1.29 1.67 ( 1 10 As of December 31, 2018, 2018 2017 2016 Options Weighted Options Weighted Options Weighted Outstanding on January 1, 1,207,600 2.61 1,427,438 2.94 917,188 2.79 Granted 165,000 2.65 260,000 2.39 575,000 3.22 Exercised – – (60,000 ) 1.91 – – Forfeited (25,000 ) 3.05 (134,750 ) 3.09 (64,750 ) 3.30 Expired – – (285,088 ) 3.99 – – Outstanding on December 31, 1,347,600 2.61 1,207,600 2.61 1,427,438 2.94 Exercisable on December 31, 772,600 2.44 598,850 2.29 774,938 2.87 Share purchase options available for grant on December 31 250,428 250,428 243,428 The following table summarizes information about options to purchase existing Shares held by the Company, or to subscribe to new Shares, at December 31, 2018: Outstanding options Fully vested options (1) Exercise price (€) Options Weighted Weighted Aggregate Options Weighted Aggregate 3.22 505,000 7.3 3.22 – 252,500 3.22 – 2.65 165,000 9.7 2.65 – – – – 2.39 210,000 8.3 2.39 – 52,500 2.39 – 2.38 120,100 1.5 2.38 – 120,100 2.38 – 1.91 297,500 4.0 1.91 – 297,5000 1.91 – 1.88 50,000 1.5 1.88 – 50,000 1.88 – 1.88 to 3.22 1,347,600 5.4 2.61 – 772,600 2.44 – ( 1 Fully vested options are all exercisable options ( 2 The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $1.85 December 31, 2018, A summary of the status of the non-vested options to purchase shares or to subscribe to new shares as of December 31, 2018, December 31, 2018, Options Weighted average Non-vested at January 1, 2018 593,750 1.53 Granted 165,000 1.33 Vested (180,000 ) 1.56 Forfeited (3,750 ) 1.29 Non-vested at December 31, 2018 575,000 1.47 As of December 31, 2018, €352 3.66 16 6 The components of accumulated other comprehensive income (loss) net of tax, for the years ended December 31, 2018, 2017, Year Ended December 31, 2018 Foreign currency Provision for Total Beginning balance (3,027 ) (577 ) (3,604 ) Other comprehensive income (loss) before reclassifications – – – Reclassified from accumulated other comprehensive loss – – – Net current-period other comprehensive income (loss) (146 ) – (146 ) Ending balance (3,173 ) (577 ) (3,748 ) Year Ended December 31, 2017 Foreign currency Provision for Total Beginning balance (3,315 ) (634 ) (3,949 ) Other comprehensive income (loss) before reclassifications – – – Reclassified from accumulated other comprehensive loss – – – Net current-period other comprehensive income (loss) 288 57 345 Ending balance (3,027 ) (577 ) (3,604 ) As there is an allowance recorded against deferred tax assets, there is no |
Note 17 - Total Sales
Note 17 - Total Sales | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | 17—TOTAL Amount of net sales derived from our operations in Asia, France, the United States. and other geographical areas, are as follows: Primary geographical markets (€) 2018 2017 2016 Asia 14,119 13,461 10,427 France 11,577 10,573 9,606 United States 2,048 1,748 3,418 Others geographical areas 11,419 9,904 12,127 39,163 35,686 35,579 The amount of net sales is recognized following the timing above: Timing of revenue recognition 2018 2017 2016 Products transferred at a point in time 31,373 28,760 29,842 Products and services transferred over time 7,790 6,927 5,737 39,163 35,686 35,579 |
Note 18 - Other Revenues
Note 18 - Other Revenues | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Other Revenues [Text Block] | 18—OTHER Other revenues consist of the following: 2018 2017 2016 Licenses and others 19 60 32 Total 19 60 32 In 2018, 2017 2016, |
Note 19 - Costs of Sales
Note 19 - Costs of Sales | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Costs of Sales [Text Block] | 19—COSTS Costs of sales consist of the following: 2018 2017 2016 Direct costs of sales (13,683 ) (12,706 ) (11,161 ) Indirect costs of sales (8,583 ) (8,232 ) (8,039 ) Total costs of sales (22,266 ) (20,938 ) (19,200 ) |
Note 20 - Research and Developm
Note 20 - Research and Development Expenses | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Research and Development Expenses [Text Block] | 20—RESEARCH Research and development expenses consist of the following: 2018 2017 2016 Gross research and development expenses (4,863 ) (4,539 ) (4,577 ) Research Tax Credit 685 504 511 Grants 90 154 198 Net Research and development expenses (4,088 ) (3,881 ) (3,868 ) In 2018, 2017 2016 Research and development costs are expensed as incurred and include amortization of assets, costs of prototypes, salaries, benefits and other headcount related costs, contract and other outside service fees, and facilities and overhead costs. |
Note 21 - Financial Income, Net
Note 21 - Financial Income, Net | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Interest Income and Interest Expense Disclosure [Text Block] | 21—FINANCIAL Interest (expense) income, net consists of the following: 2018 2017 2016 Interest income 19 18 21 Interest expense (111 ) (44 ) (57 ) Warrants exercised / forfeited 889 625 174 Changes in fair value of Financial Instrument (1) – 2,044 3,811 Total 797 2,643 3,949 ( 1 For more details on the fair value of Financial Instruments, please refer to Notes 14 2 25. |
Note 22 - Income Taxes
Note 22 - Income Taxes | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 22—INCOME 22 1 Income / (loss) before income taxes is comprised of the following: 2018 2017 2016 France 1,687 1,003 4,936 Other countries (1,667 ) (1,296 ) (492 ) Total 20 (293 ) 4,444 22 2 Income tax (expense)/benefit consists of the following: 2018 2017 2016 Current income tax expense: France (163 ) (161 ) (323 ) Other countries (351 ) (373 ) (249 ) Sub-total current income tax expense (515 ) (534 ) (572 ) Deferred income tax (expense) benefit: France 2 (15 ) (2 ) Other countries 155 161 (30 ) Sub-total deferred income tax (expense) benefit 157 146 (32 ) Total (358 ) (388 ) (602 ) 22 3 Deferred income taxes reflect the impact of temporary differences between the amounts of assets and liabilities reported for financial reporting purposes and such amounts as measured in accordance with tax laws. The tax effects of temporary differences which give rise to significant deferred tax assets (liabilities) are as follows by nature: December 31, 2018 2017 Net operating loss carry forwards 13,675 13,218 Elimination of intercompany profit in inventory 187 167 Elimination of intercompany profit in fixed assets 343 265 Provisions for retirement indemnities 488 566 Capital leases treated as operating leases for tax 10 (3 ) Other items 174 216 Total deferred tax assets 14,877 14,431 Total deferred tax liabilities – – Net deferred tax assets 14,877 14,431 Valuation allowance for deferred tax assets (14,553 ) (14,266 ) Deferred tax assets (liabilities), net of allowance 324 165 Net operating loss carryforwards available amounts to €57,595 December 31, 2018, €32,535 €21,229 €2,342 €1,489 €13,675 December 31, 2018. December 31, 2018, €55,253 €57,595 no 2019 2029. 740, not not The 2017 December 22, 2017. 2017 2018, 15% 39% 21% $100K 2018 Starting from tax year 2018, 33.33% 25% 2022. 22 4 A reconciliation of differences between the statutory French income tax rate and the Company’s effective tax income (loss) is as follows: 2018 2017 2016 Effective income / (loss) tax at French statutory tax rate (6 ) 98 (1,480 ) Income of foreign subsidiaries taxed at different tax rates (124 ) 64 109 Effect of net operating loss carry-forwards and valuation allowances (210 ) (1,530 ) 115 Non-taxable debt fair value variation 235 1,026 1,207 Permanent differences (392 ) 178 217 Effect of cancellation of intra-group positions 35 144 – French business tax included in income tax (CVAE) (161 ) (161 ) (152 ) Other 265 (207 ) (617 ) Effective income (loss) tax (358 ) (388 ) (602 ) 22 5 According to ASC 740, December 31, 2018 no The Company remains subject to examination by major tax jurisdictions. Interest and penalties on income taxes are classified as a component of the provision for income taxes. There were no 2016, 2017 2018. |
Note 23 - Earnings (Loss) Per S
Note 23 - Earnings (Loss) Per Share | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 23—EARNINGS December 31, December 31, December 31, Income (loss) available to common shareholders (in Euros) (€338,38)2 (€681,345) €3,842,201 Number of shares for the computation of basic EPS 28,997,866 28,961,928 27,823,313 Basic EPS (in Euros) (€0.01) (€0.02) €0.14 Effect of dilutive securities 347,500 581,915 1,542,270 Number of shares for the computation of diluted EPS 28,997,866 28,961,928 29,365,583 Diluted EPS income / (loss) (in Euros) (€0.01) (€0.02) €0.13 Diluted EPS income / (loss) available to common shareholders is computed including assumed conversions as all dilutive securities, consisting of stock options and warrants are out of the money. The effects of dilutive securities for the years ended December 31, 2017 2018 |
Note 24 - Commitments and Conti
Note 24 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 24—COMMITMENTS 24 1 The Company currently has commitments regarding its operating leases as described in Note 12 2. 24 2 The Company currently has contingencies relating to warranties provided to customers for products as described in Note 1 15 11. |
Note 25 - Fair Value of Financi
Note 25 - Fair Value of Financial Instruments | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 25—FAIR The following disclosure of the estimated fair value of financial instruments was made in accordance with the requirements of ASC 820 ASC 820 three may Level 1: Level 2: 1 Level 3: ASC 820 December 31, December 31, Assets: Cash and cash equivalents Level 1 19,464 20,004 Liabilities: Short-term borrowings Level 1 3,683 2,718 Long-Term Debt Level 1 1,830 1,217 Investor Warrants Level 3 – 840 The recorded amount of cash and cash equivalents, short term investment and short-term borrowings are a reasonable estimate of their fair value due to the short-term maturities of these instruments. The fair market value (Level 1 14 1 Concerning Investor and Placement Agent Warrants, the Company uses a Black-Scholes option pricing model. The fair value of the Warrants changed over time depending on the volatility and share price at balance sheet date (see note 14 2 The following tables provide a reconciliation of fair value for which the Company used Level 3 December 31, 2016 December 31, 2018 : All amounts in Investor Investor Investor Total Financial As of December 31, 2016 640 1,118 2,162 3,921 Warrants forfeited (see note 21) (1) (489 ) – – (489 ) Warrants exercises (see note 21) (1) (136 ) – – (136 ) FV adjustments (see note 21) (1) – (656 ) (1,388 ) (2,044 ) USD/EUR exchange impact (2) (16 ) (135 ) (262 ) (412 ) As of December 31, 2017 – 328 512 840 FV adjustments (see note 21) (1) – (345 ) (544 ) (889 ) USD/EUR exchange impact (2) – 17 32 49 As of December 31, 2018 – – – – ( 1 ( 2 Please refer to “Note 14 |
Note 26 - Concentration of Cred
Note 26 - Concentration of Credit Risk | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | 26—CONCENTRATION Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and trade accounts and notes receivable from customers, primarily located in France, Japan and the United States. The Company maintains cash deposits with major banks. Management periodically assesses the financial condition of these institutions and believes that credit risk is limited. The Company has procedures in effect to monitor the creditworthiness of its customers. The Company obtains bank guarantees for first €1.4 €1.0 December 31, 2018 2017, Actual losses may In 2018, 2017 2016, not 10% |
Note 27 - Foreign Currency Tran
Note 27 - Foreign Currency Transactions | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Foreign Currency Disclosure [Text Block] | 27—FOREIGN The Company generates a significant percentage of its revenues, and of its operating expenses, in currencies other than euro. The Company’s operating profitability could be materially adversely affected by large fluctuations in the rate of exchange between the euro and such other currencies. The Company engages in foreign exchange hedging activities when it deems necessary, but there can be no December 31, 2018, no |
Note 28 - Segment Information
Note 28 - Segment Information | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 28—SEGMENT The Company currently has two 2018, 2017 2016 2018, 2017 2016. The business in which the Company operates is the development and production of minimally invasive medical devices, primarily for the treatment of urological diseases. Substantially all revenues result from the sale of medical devices and their related license and royalty payments from third Segment operating profit or loss and segment assets are determined in accordance with the same policies as those described in the summary of significant accounting policies. Interest income and expense, current and deferred income taxes are not 2018 2017 2016 Segment operating income (loss) (1,315 ) (2,027 ) 392 Financial income (expense), net 797 2,643 3,949 Foreign Currency exchange (losses) gains, net 538 (909 ) 103 Income tax (expense) credit (358 ) (388 ) (602 ) Consolidated net profit (loss) (338 ) (681 ) 3,842 A summary of the Company’s operations by segment is presented below for years ending December 31, 2018, 2017 2016: HIFU Division UDS Division Reconciling (1) Total consolidated 2018 Sales of goods 5,494 19,576 – 25,070 Sales of RPPs & leases 3,750 1,336 – 5,086 Sales of spare parts and services 1,780 7,227 – 9,007 Total sales 11,025 28,139 – 39,163 External other revenues 19 – – 19 Total revenues 11,044 28,139 39,183 Total COS (5,312 ) (16,954 ) – (22,266 ) Gross profit 5,732 11,185 – 16,917 R&D expenses (2,394 ) (1,694 ) – (4,088 ) Selling and marketing expenses (4,628 ) (5,923 ) – (10,551 ) G&A expenses (1,036 ) (1,311 ) (1,246 ) (3,593 ) Total expenses (8,057 ) (8,928 ) (1,246 ) (18,232 ) Operating income (loss) from operations (2,325 ) 2,257 (1,246 ) (1,315 ) Total Assets 13,648 29,849 5,243 48,740 Capital expenditures 1,154 775 – 1,928 Long-lived assets 2,855 5,158 – 8,013 Goodwill 645 1,767 – 2,412 HIFU Division UDS Division Reconciling (1) Total consolidated 2017 Sales of goods 4,232 18,348 – 22,580 Sales of RPPs & leases 3,800 1,295 – 5,095 Sales of spare parts and services 1,445 6,566 – 8,011 Total sales 9,477 26,209 – 35,686 External other revenues 36 24 – 60 Total revenues 9,513 26,233 35,746 Total COS (4,732 ) (16,207 ) – (20,938 ) Gross profit 4,782 10,026 – 14,808 R&D expenses (2,469 ) (1,413 ) – (3,881 ) Selling and marketing expenses (4,004 ) (5,521 ) – (9,526 ) G&A expenses (1,009 ) (1,057 ) (1,362 ) (3,428 ) Total expenses (7,482 ) (7,991 ) (1,362 ) (16,835 ) Operating income (loss) from operations (2,701 ) 2,035 (1,362 ) (2,027 ) Total Assets 11,333 27,803 7,761 46,897 Capital expenditures 1,190 928 – 2,118 Long-lived assets 2,804 4,278 – 7,082 Goodwill 645 1,767 – 2,412 HIFU Division UDS Division Reconciling (1) Total consolidated 2016 Sales of goods 9,382 14,664 – 24,045 Sales of RPPs & leases 3,547 1,359 – 4,906 Sales of spare parts and services 862 5,766 – 6,628 Total sales 13,791 21,789 – 35,579 External other revenues 28 4 – 32 Total revenues 13,819 21,792 35,611 Total COS (5,710 ) (13,490 ) – (19,200 ) Gross profit 8,109 8,302 – 16,411 R&D expenses (2,452 ) (1,416 ) – (3,868 ) Selling and marketing expenses (3,888 ) (4,968 ) – (8,856 ) G&A expenses (804 ) (1,177 ) (1,315 ) (3,296 ) Total expenses (7,144 ) (7,560 ) (1,315 ) (16,019 ) Operating income (loss) from operations 964 742 (1,315 ) 392 Total Assets 11,680 24,202 10,709 46,591 Capital expenditures 1,013 608 – 1,621 Long-lived assets 1,775 3,812 192 5,779 Goodwill 645 1,767 – 2,412 ( 1 For years 2016 2017, |
Note 29 - Valuation Accounts
Note 29 - Valuation Accounts | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] | 29—VALUATION Allowance for Allowance for Slow-moving Warranty Balance as of December 31, 2015 19,212 1,091 728 576 Charges to costs and expenses 238 103 121 319 Deductions: write-off and others (233 ) (46 ) (347 ) Balance as of December 31, 2016 19,450 960 803 548 Charges to costs and expenses 1,536 69 239 316 Deductions: write-off and others (6,720 ) – (319 ) (415 ) Balance as of December 31, 2017 14,266 1,029 723 449 Charges to costs and expenses 515 365 355 433 Deductions: write-off and others (228 ) 10 (104 ) (334 ) Balance as of December 31, 2018 14,553 1,404 974 548 |
Note 30 - Supplemental Disclosu
Note 30 - Supplemental Disclosures of Cash Flow Information | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Cash Flow, Supplemental Disclosures [Text Block] | 30—SUPPLEMENTAL Interest and income taxes paid are as follows: 2018 2017 2016 Income taxes paid (refunds received) 407 585 596 Interest paid 49 41 41 Interest received 12 7 4 Non-cash transactions: 2018 2017 2016 Capital lease obligations incurred 427 484 285 |
Note 31 - Related Party Transac
Note 31 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 31—RELATED The General Manager of the Company's Korean branch "EDAP-TMS Korea", who resigned from his position with EDAP on October 11, 2017, no no October 11, 2017, €41 €62 2017 2016 December 31, 2018 2017, no Dae You has purchased medical devices from us, which it operates in partnership with hospitals or clinics. These purchases (‘Sales of goods’) amounted to €161 €483 2017 2016, December 31, 2018 2017, no In 2018, 80,000,000 November 27, 2018. In 2018, 90,000 January 29, 2019. |
Note 32 - Subsequent Events
Note 32 - Subsequent Events | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 32—SUBSEQUENT There were no |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies [Abstract] | |
Nature of Operations [Policy Text Block] | 1 1 EDAP TMS S.A. and its subsidiaries (‘‘the Company’’) are engaged in the development, production, marketing, distribution and maintenance of a portfolio of minimally-invasive medical devices for the treatment of urological diseases. The Company currently produces innovative robotic devices for treating stones of the urinary tract and localized prostate cancer. We also derive revenues from the distribution of urodynamics products and urology lasers. Net sales consist primarily of direct sales to hospitals and clinics in France and Europe, export sales to third Moreover, the Company develops a novel HIFU treatment for liver cancer in cooperation with its long-term academic partner INSERM and leading cancer centers (the “HECAM” project). The Company purchases the majority of the components used in its products from a number of suppliers but for some components, relies on a single source. Delay would be caused if the supply of these components or other components was interrupted and these delays could be extended in certain situations where a component substitution may |
Basis of Accounting, Policy [Policy Text Block] | 1 2 These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). With the exception of the change in the Company’s Revenue Recognition Policy as a result of the adoption of ASC 606, no December 31, 2018, |
Use of Estimates, Policy [Policy Text Block] | 1 3 The preparation of financial statements in conformity with U.S. generally accepted accounting principles (‘‘U.S. GAAP’’) requires management to make estimates and assumptions, such as business plans, stock price volatility, duration of standard warranty per market, price of maintenance contract used to determine the amount of revenue to be deferred and life duration of our range of products. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Consolidation, Policy [Policy Text Block] | 1 4 The accompanying consolidated financial statements include the accounts of EDAP TMS S.A. and all its domestic and foreign owned subsidiaries. |
Revenue Recognition, Policy [Policy Text Block] | 1 5 The Company adopted ASC Topic 606, Revenue from Contracts with Customers January 1, 2018. The Company’s revenue consists of: - Sales of goods (devices and consumables), where invoicing takes place upon delivery. - Revenue-per-Procedures (“RPP”) and leases: they comprise (i) revenues on a per treatment basis which are invoiced after each treatment, or in advance, or on a periodic basis, (ii) leases of devices, which are generally invoiced on a monthly or quarterly basis, and (iii) lease components arising from multiple-element arrangements, where specific sales terms are negotiated in accordance with each customer’s individual requirements and which are generally invoiced based on contract terms, - Sales of spare parts and services (maintenance, upgrades, mobility and others). Spare parts are invoiced when delivered. Regarding services, invoicing is performed either on a subscription basis (in advance or at the end of the period) or when performed. The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due between one three The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the goods or services and their payment terms can be identified, the contract has commercial substance, collectability of the contract consideration is probable, it is approved and the parties are committed to their obligations. Our sale arrangements may may not For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the goods or services. If a standalone selling price is not not The Company recognizes revenue when the performance obligations are satisfied by transferring control over the good or service to a customer. The Company’s revenue consists of the following: Sales of goods: Sales of goods are and have historically been comprised of net sales of medical devices (ESWL lithotripters and HIFU devices) and net sales of disposables (mostly Ablapaks and Focalpaks in the HIFU division and electrodes in the UDS division). Sales of goods also includes products such as urology laser and urodynamics devices distributed through our agents and third For devices and disposables, revenue is recognized when the Company transfers control to the customer (i.e. when the customer has the ability to direct the use of, and obtain substantially all of the remaining benefit from, the device or disposables), which is generally at the point of delivery or installation, depending on the terms of the arrangement (i.e. when the customer can use the good to provide services or sell or exchange the good), and based on contractual incoterms. The Company’s sales arrangements do not one two not Sales of RPPs and leases: Sales of RPP and leases include the revenues from the sale of treatment procedures and from the leasing of machines. We provide machines to clinics and hospitals for free for a limited period, rather than selling the devices. These hospitals and clinics perform treatments using the devices and usually pay us based on the number of individual treatments provided. Revenues related to the sale of treatments invoiced on a ‘‘Revenue-Per-Procedure’’ (‘‘RPP’’) basis are recognized when the treatment procedure has been completed. Revenues from devices leased to customers under operating leases are recognized on a straight-line basis. Regarding multiple-element arrangements with a lease component, a portion of the contract is allocated to the lease component on the basis of observable market prices applied by the Company for similar devices under operating leases. The lease component is recognized on a straight line basis over the contractual period. Other components under the contract are recognized in accordance with their nature. Sales of spare parts and services: Revenues related to spare parts are recognized when spare parts are delivered to distributors who perform their own maintenance services. Spare parts used in the performance of EDAP’s own maintenance and repair services are generally not Revenues related to Services mainly consist of maintenance contracts which rarely exceed one no not The Company recognizes revenue for extended warranties included in the multiple-element arrangements as a separate performance obligation in Sales of services on a straight-line basis over the extended warranty period. In the majority of countries in which the Company operates, the statutory warranty period is one two not Agents and distributors: As part of its sale process in countries other than continental France, when the Company does not Deferred revenue: Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed, and consists primarily of billing or cash receipts in advance of services due under maintenance contracts or extended warranty contracts. The associated deferred revenue is generally recognized ratably over the service period. Disaggregation of revenue: Disaggregation by primary geographical market, and timing of revenue recognition is reported in Note 17. Contract Balances: Details on contract liabilities are reported on Note 10. The Company applies the practical expedient in paragraph 606 10 50 14 not one |
Cost of Sales, Policy [Policy Text Block] | 1 6 Costs of sales include all direct product costs, costs related to shipping, handling, duties and importation fees, as well as certain indirect costs such as service and supply chain departments expenses. Indirect costs are allocated by type of sales (goods, RPP and leases, spare parts and services) using an allocation method determined by management by type of costs and segment activities and reviewed on an annual basis. |
Revenue from Contract with Customer, Shipping and Handling Costs, Policy [Policy Text Block] | 1 7 Shipping and handling costs are not |
Cash and Cash Equivalents, Policy [Policy Text Block] | 1 8 Cash equivalents are cash investments which are highly liquid and have initial maturities of 90 Cash investments with a maturity higher than 90 |
Receivables, Policy [Policy Text Block] | 1 9 Accounts receivables are stated at cost net of allowances for doubtful accounts. The Company makes judgments as to its ability to collect outstanding receivables and provides allowances for the portion of receivables when collection becomes doubtful. Provision is made based upon a specific review of all significant outstanding invoices. These estimates are based on our bad debt write-off experience, analysis of credit information, specific identification of probable bad debt based on our collection efforts, aging of accounts receivables and other known factors. Accounts receivable also include factored receivables for which the Company is bearing the collection risk. |
Inventory, Policy [Policy Text Block] | 1 10 Inventories are valued at the lower of cost and net realizable value. Cost is either the manufacturing cost, which is principally comprised of components and labor costs for our own manufactured products, or purchase price for urology products we distribute. Cost is determined on a first first first |
Property, Plant and Equipment, Policy [Policy Text Block] | 1 11 Property and equipment is stated at historical cost. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful life of the related assets, as follows: Leasehold improvements (in years) 10 or lease term if shorter Equipment (in years) 3 - 10 Furniture, fixtures, fittings and other (in years) 2 - 10 Equipment includes industrial equipment and research equipment that has alternative future uses. Equipment also includes devices that are manufactured by the Company and leased to customers through operating leases related to Revenue-Per-Procedure transactions and devices subject to sale and leaseback transactions. This equipment is depreciated over a period of seven |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | 1 12 The Company reviews the carrying value of its long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not not |
Goodwill and Intangible Assets, Policy [Policy Text Block] | 1 13 Goodwill represents the excess of purchase price over the fair value of identifiable net assets of businesses acquired. Goodwill is not 350, two first second second Changes in market conditions could have a major impact on the valuation of these assets and could result in additional impairment losses. Intangible assets consist primarily of purchased patents relating to lithotripters, purchased licenses, a purchased trade name and a purchased trademark. The basis for valuation of these assets is their historical acquisition cost. Amortization of intangible assets is calculated by the straight-line method over the shorter of the contractual or estimated useful life of the assets, as follows: Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7 |
Stockholders' Equity, Policy [Policy Text Block] | 1 14 Treasury stock purchases are accounted for at cost. The sale of treasury stocks is accounted for using the first first not 10% |
Standard Product Warranty, Policy [Policy Text Block] | 1 15 The Company provides customers with a warranty for each product sold and accrues warranty expense at time of sale based upon historical claims experience. Standard warranty period may 1 2 €433 €316 €319 December 31, 2018, 2017 2016, |
Income Tax, Policy [Policy Text Block] | 1 16 The Company accounts for income taxes in accordance with ASC 740, 740, not not ASC740, no Under ASC740, not |
Research, Development, and Computer Software, Policy [Policy Text Block] | 1 17 Research and development costs are recorded as an expense in the period in which they are incurred. The French government provides tax credits to companies for innovative research and development. This tax credit is calculated based on a percentage of eligible research and development costs and it can be refundable in cash and is not |
Advertising Costs, Policy [Policy Text Block] | 1 18 Advertising costs are recorded as an expense in the period in which they are incurred and are included in selling and administrative expenses in the accompanying consolidated statements of income (loss). Advertising costs amounted to €719 €672 €744 December 31, 2018, 2017 2016, |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | 1 19 Translation of the financial statements of consolidated companies The reporting currency of EDAP TMS S.A. for all years presented is the euro (€). The functional currency of each subsidiary is its local currency. In accordance with ASC 830, · · · · Foreign currencies transactions Transactions involving foreign currencies are translated into the functional currency using the exchange rate prevailing at the time of the transactions. Receivables and payables denominated in foreign currencies are translated at year-end exchange rates. The resulting unrealized exchange gains and losses are carried to the statement of income. Presentation in the Statement of Income Aggregate foreign currency transactions gains and losses are disclosed in a single caption in the Statement of Income under section “Foreign currency exchange gain (loss), net”. |
Earnings Per Share, Policy [Policy Text Block] | 1 20 Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted earnings per share reflects potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. The dilutive effects of the Company’s common stock options and warrants is determined using the treasury stock method to measure the number of shares that are assumed to have been repurchased using the average market price during the period, which is converted from U.S. dollars at the average exchange rate for the period. |
Derivatives, Policy [Policy Text Block] | 1 21 ASC 815 Gains and losses from derivative instruments are recorded in the Statement of Income. |
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | 1 22 At December 31, 2018, four 718 |
Debt, Policy [Policy Text Block] | 1 23 The Company recorded outstanding warrants issued in March 2012, May 2013 April 2016 815 40 15 7 not December 31, 2018, no |
Lessee, Leases [Policy Text Block] | 1 24 In accordance with ASC 840, one - Ownership is transferred to the lessee by the end of the lease term; - The lease contains a bargain purchase option; - The lease term is at least 75% - The present value of the minimum lease payments at the beginning of the lease term is 90% For sales type leases, the following two - Collectability of the minimum lease payment is reasonably predictable; - No The Company enters into sale and leaseback transactions from time to time. In accordance with ASC 840, |
New Accounting Pronouncements, Policy [Policy Text Block] | 1 25 Recently Adopted Accounting Pronouncements In July 2015, 2015 14 2015 14 No. 2014 09, Revenue from Contracts with Customers 606 one 606supersedes 605 The Company adopted Topic 606 Revenue from Contracts with Customers January 1, 2018. The Company applied Topic 606 using the cumulative effect method i.e. by recognizing the cumulative effect of initially applying Topic 606 January 1, 2018. not 605. In implementing Topic 606, December 31, 2018 2017. 606, not The impact to the Company of adopting the new revenue standard primarily relates to additional and expanded disclosures, and in particular contract liabilities and disaggregated revenues. There is no 2018 In November 2015, No. 2015 17, Balance Sheet Classification of Deferred Taxes 2015 17 2015 17 first 2017. 2015 17 December 31, 2017. In March 2016, 2016 09, 2016 09 2016 09 15 December 2016, No 2016 09. Recent Accounting Pronouncements Not In February 2016, No. 2016 02, 2016 02 840 842 12 December 15, 2018 January 1, 2019. not January 1, 2019, 2.9 In January 2017, 2017 04, 2 not first 2020. January 1, 2017. |
Note 1 - Summary of Significa_2
Note 1 - Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Property, Plant, and Equipment, Estimated Useful Life [Table Text Block] | Leasehold improvements (in years) 10 or lease term if shorter Equipment (in years) 3 - 10 Furniture, fixtures, fittings and other (in years) 2 - 10 |
Amortizable Intangible Assets, Useful Life [Table Text Block] | Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7 |
Note 2 - Cash Equivalents (Tabl
Note 2 - Cash Equivalents (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Cash and Cash Equivalents [Table Text Block] | December 31, 2018 2017 Total cash and cash equivalents 19.464 20,004 Short term investments – – Total cash and cash equivalents, and short term investments 19,464 20,004 |
Note 3 - Trade Accounts and N_2
Note 3 - Trade Accounts and Notes Receivable, Net (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] | December 31, 2018 2017 Trade accounts receivable 12,907 12,202 Notes receivable 408 181 Less: allowance for doubtful accounts (1,405 ) (1,029 ) Total 11,910 11,354 Less current portion (11,884 ) (11,277 ) Total long-term portion 26 77 |
Schedule of Financing Receivables, Minimum Payments [Table Text Block] | Sales type 2019 42 2020 18 2021 8 2022 – 2022 – Total minimum payments 70 |
Note 4 - Other Receivables (Tab
Note 4 - Other Receivables (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Other Receivables [Table Text Block] | December 31, 2018 2017 Research and development tax credit receivable from the French State 685 560 Value-added taxes receivable 390 216 Other receivables from Government and public authorities 233 238 Others 126 52 Total 1,434 1,066 |
Note 5 - Inventories (Tables)
Note 5 - Inventories (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | December 31, 2018 2017 Components, spare parts 3,496 3,909 Work-in-progress 576 729 Finished goods – own manufactured products 2,672 1,167 Finished goods – distribution products 1,442 1,656 Total gross inventories 8,186 7,461 Less: allowance for slow-moving inventory and net realizable value (974 ) (722 ) Total 7,212 6,739 |
Note 6 - Other Assets (Tables)
Note 6 - Other Assets (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Other Assets [Table Text Block] | December 31, 2018 2017 Prepaid expenses, current portion 382 489 Total 382 489 |
Note 7 - Property and Equipme_2
Note 7 - Property and Equipment, Net (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | December 31, 2018 2017 Equipment 8,677 7,588 Furniture, fixture, and fittings and other 4,064 3,766 Total gross value 12,742 11,354 Less: accumulated depreciation and amortization (8,534 ) (7,672 ) Total 4,208 3,682 |
Note 8 - Goodwill and Intangi_2
Note 8 - Goodwill and Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | December 31, 2018 2017 Licenses 1,431 993 Trade name and trademark 414 393 Patents 412 412 Organization costs 320 320 Total gross value 2,577 2,118 Accumulated amortization for licenses (587 ) (477 ) Accumulated amortization for trade name and trademark (411 ) (383 ) Accumulated amortization for patents (412 ) (411 ) Accumulated amortization for organization costs (320 ) (320 ) Less: Total accumulated amortization (1,730 ) (1,591 ) Total 847 527 |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | December 31, 2019 97 2020 89 2021 87 2022 85 2023 83 Total 441 |
Note 9 - Trade Accounts and N_2
Note 9 - Trade Accounts and Notes Payable (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | December 31, 2018 2017 Trade accounts payable 6,286 6,220 Notes payable 11 90 Total 6,297 6,310 |
Note 10 - Deferred Revenues (Ta
Note 10 - Deferred Revenues (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Contract with Customer, Asset and Liability [Table Text Block] | December 31, 2018 2017 Deferred revenues on maintenance contracts 1,246 1,497 Deferred revenue on RPP 339 405 Deferred revenue on sale of devices 289 218 Deferred revenue on extension of warranty, included in sales contracts 855 676 Deferred research and development grants 173 61 Total 2,902 2,857 Less long term portion (973 ) (562 ) Current portion 1,929 2,295 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] | December 31, 2019 167 2020 264 2021 218 2022 162 2023 44 Total 855 |
Change in Contract with Customer, Liability [Table Text Block] | <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; text-align: left">Beginning balance </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">676</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New extension of warranty </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">331</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Recognition of revenue </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(152</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">855</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"> </td> </tr> </table></div>" id="sjs-B6"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; text-align: left">Beginning balance </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">676</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New extension of warranty </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">331</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Recognition of revenue </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(152</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">855</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"> </td> </tr> </table></div> |
Note 11 - Other Accrued Liabi_2
Note 11 - Other Accrued Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | December 31, 2018 2017 Retirement indemnities 2,287 2,076 Provision for warranty costs 547 449 Accruals for payroll and associated taxes 680 611 Conditional government advances 1,039 1,039 Value added tax payable 327 125 Advances received from customers 115 108 Provision for Asset Retirement Obligation (Japan) 118 100 Provision for employee termination indemnities (Italy) 369 349 Provision for employee termination indemnities (Korea) 30 – Others 411 360 Total 5,923 5,217 Less non-current portion (3,800 ) (3,681 ) Current portion 2,122 1,536 |
Schedule of Conditional Advances [Table Text Block] | 2019 – 2020 – 2021 – 2022 203 2023 and thereafter 836 Total 1,039 |
Schedule of Product Warranty Liability [Table Text Block] | December 31, 2018 2017 Beginning of year 449 548 Amount used during the year (335 ) (415 ) New warranty expenses 433 316 End of year 547 449 Less current portion (356 ) (265 ) Long term portion 191 184 |
Note 12 - Lease Obligations (Ta
Note 12 - Lease Obligations (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] | December 31, 2019 401 2020 361 2021 252 2022 170 2023 and thereafter 89 Total minimum lease payments 1273 Less: amount representing interest (39 ) Present value of minimum lease payments 1,234 Less: current portion (383 ) Long-term portion 852 |
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | France Japan USA Italy 2019 329 227 45 37 2020 329 167 45 37 2021 329 132 4 37 2022 329 39 – 25 2023 and thereafter 822 – – – Total 2,138 565 94 135 |
Note 14 - Long Term Debt and _2
Note 14 - Long Term Debt and Financial Instruments Carried at Fair Value (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | December 31, 2018 2017 France term loan 526 700 Japanese term loan (YEN) 628 40 Germany term loan 632 399 Italy term loan 27 78 Malaysia term loan 17 – Total long term debt 1,830 1,217 Less current portion (491 ) (383 ) Total long-term portion 1,339 834 |
Schedule of Long-term Debt Instruments [Table Text Block] | Initial Maturity Fixed Interest rate Frequency of EDAP Technomed Co. Ltd 80,000,000 November 30, 2025 1.98 % Monthly instalment Initial Maturity Fixed Interest rate Frequency of EDAP Technomed Co. Ltd 55,000,000 June 30, 2018 1.80 % Monthly instalment 10,000,000 June 30, 2018 2.10 % Monthly instalment Initial Maturity Fixed Interest rate Frequency of EDAP TMS GMBH 450,000 November 30, 2020 2.49 % Monthly instalment Initial Maturity Fixed Interest rate Frequency of EDAP TMS GMBH 136,500 December 31, 2022 2.25 % Monthly instalment Initial Maturity Fixed Interest rate Frequency of EDAP TMS GMBH 400,000 April 30, 2023 2.40 % Monthly instalment Initial Maturity Fixed Interest rate Frequency of EDAP TMS FRANCE 700,000 October 16, 2021 0.40 % Quarterly instalment Initial Maturity Fixed Interest rate Frequency of EDAP TECHNOMED SDN BHD 90,000 July 31, 2022 4.64 % Monthly instalment |
Schedule of Derivative Instruments [Table Text Block] | December 31, 2018 2017 Investor Warrants – 840 – Total – 840 Less current portion – (840 ) Total long-term portion – – |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | At inception December 31, December 31, Share price at closing date $3.96 – $2.87 Strike price of warrants $4.25 – $4.25 Risk free interest rate at 5.5 years 1.07% – 0% Share price volatility 71% – 57.40% Dividend rates 0% – 0% Unit fair value $2.35 – $0.26 Total fair value (in thousand $) $3,525 – $392 Total equivalent amount (in thousand €) €2,725 – €328 At inception December 31, December 31, Share price at closing date 3.64 – 2.87 Strike price of warrants $4.50 – $4.50 Risk free interest rate at 2.5 years 0% – 0% Share price volatility 60.20% – 57.40% Dividend rates 0% – 0% Unit fair value $1.09 – $0.19 Total fair value (in thousand $) $3,579 – $614 Total equivalent amount (in thousands €) €3,168 – €512 |
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] | 2019 491 2020 460 2021 381 2022 205 2023 and thereafter 293 Total 1,830 |
Note 15 - Other Long-term Lia_2
Note 15 - Other Long-term Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Other Long-term Liabilities [Table Text Block] | <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> <td style="font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Provision for retirement indemnities (Japan & France), less current portion </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,222</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,008</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Provision for employee termination indemnities (Italy) less current portion </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">170</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Provision for employee termination indemnities (Korea) less current portion </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">–</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Provision for Asset Retirement Obligation (Japan) less current portion </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">118</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Provision for warranty costs, less current portion </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">191</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">184</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conditional government advances, less current portion </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,039</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,039</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accrued interest less current portion </td> <td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">–</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total </td> <td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,800</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3,68 1</div></div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"> </td> </tr> </table></div>" id="sjs-B4"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> <td style="font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Provision for retirement indemnities (Japan & France), less current portion </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,222</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,008</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Provision for employee termination indemnities (Italy) less current portion </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">170</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Provision for employee termination indemnities (Korea) less current portion </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">–</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Provision for Asset Retirement Obligation (Japan) less current portion </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">118</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Provision for warranty costs, less current portion </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">191</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">184</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conditional government advances, less current portion </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,039</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,039</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accrued interest less current portion </td> <td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">–</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total </td> <td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,800</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3,68 1</div></div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"> </td> </tr> </table></div> |
Schedule of Assumptions Used [Table Text Block] | Pension Benefits - France 2018 2017 Discount rate 1.60 % 1.60 % Salary increase 2.50 % 2.50 % Retirement age 65 65 Average retirement remaining service period 24 24 Pension Benefits - Japan 2018 2017 Discount rate 0.50 % 0.50 % Salary increase 2.50 % 2.50 % Retirement age 60 60 Average retirement remaining service period 14 14 |
Schedule of Amounts Recognized in Balance Sheet [Table Text Block] | France Japan Non-current liabilities 966 1,255 Current liabilities 10 55 Accumulated other comprehensive income (loss) (161 ) (416 ) Total 815 895 France Japan Non-current liabilities 867 1,141 Current liabilities 27 40 Accumulated other comprehensive income (loss) (165 ) (412 ) Total 729 769 |
Schedule of Defined Benefit Plans Disclosures [Table Text Block] | France 2018 2017 2016 Change in benefit obligations: Benefit obligations at beginning of year 895 842 694 Service cost 67 66 45 Interest cost 14 13 15 Actuarial (gain) / loss – – 88 Amortization of net prior service cost 1 1 – Benefits paid – (27 ) – Benefit obligations at end of year (1) 976 895 842 Unrecognized actuarial (gain) loss (2) 141 144 147 Unrecognized prior service cost (2) 20 22 23 Accrued pension cost 815 729 672 Japan 2018 2017 2016 Change in benefit obligations: Benefit obligations at beginning of year 1,182 1,162 906 Service cost 131 118 81 Interest cost 6 6 10 Amortization of net loss 26 24 16 Actuarial (gain) / loss – (12 ) 147 Benefits paid (94 ) (17 ) (38 ) Exchange rate impact (60 ) (99 ) 40 Benefit obligations at end of year (1) 1,311 1,182 1,162 Unrecognized actuarial (gain) loss (2) 416 412 464 Unrecognized prior service cost (2) – – – Accrued pension cost 895 769 698 |
Schedule of Expected Benefit Payments [Table Text Block] | France Japan 2019 10 55 2020 – 6 2021 86 55 2022 – 75 2023 107 96 2024-2028 277 743 |
Note 16 - Shareholders' Equity
Note 16 - Shareholders' Equity (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Year Ended December 31, 2018 2017 2016 Weighted-average expected life (years) 6.25 6.25 6.25 Expected volatility rates (1) 52.6 % 57.4 % 60.60 % Expected dividend yield 0 % 0 % 0 % Risk-free interest rate 0.18 % 0.02 % 0.01 % Weighted-average exercise price (€) 2.65 2.39 3.22 Weighted-average fair value of options granted during the year (€) 1.33 1.29 1.67 |
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] | 2018 2017 2016 Options Weighted Options Weighted Options Weighted Outstanding on January 1, 1,207,600 2.61 1,427,438 2.94 917,188 2.79 Granted 165,000 2.65 260,000 2.39 575,000 3.22 Exercised – – (60,000 ) 1.91 – – Forfeited (25,000 ) 3.05 (134,750 ) 3.09 (64,750 ) 3.30 Expired – – (285,088 ) 3.99 – – Outstanding on December 31, 1,347,600 2.61 1,207,600 2.61 1,427,438 2.94 Exercisable on December 31, 772,600 2.44 598,850 2.29 774,938 2.87 Share purchase options available for grant on December 31 250,428 250,428 243,428 |
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] | Outstanding options Fully vested options (1) Exercise price (€) Options Weighted Weighted Aggregate Options Weighted Aggregate 3.22 505,000 7.3 3.22 – 252,500 3.22 – 2.65 165,000 9.7 2.65 – – – – 2.39 210,000 8.3 2.39 – 52,500 2.39 – 2.38 120,100 1.5 2.38 – 120,100 2.38 – 1.91 297,500 4.0 1.91 – 297,5000 1.91 – 1.88 50,000 1.5 1.88 – 50,000 1.88 – 1.88 to 3.22 1,347,600 5.4 2.61 – 772,600 2.44 – |
Schedule of Nonvested Share Activity [Table Text Block] | Options Weighted average Non-vested at January 1, 2018 593,750 1.53 Granted 165,000 1.33 Vested (180,000 ) 1.56 Forfeited (3,750 ) 1.29 Non-vested at December 31, 2018 575,000 1.47 |
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | Year Ended December 31, 2018 Foreign currency Provision for Total Beginning balance (3,027 ) (577 ) (3,604 ) Other comprehensive income (loss) before reclassifications – – – Reclassified from accumulated other comprehensive loss – – – Net current-period other comprehensive income (loss) (146 ) – (146 ) Ending balance (3,173 ) (577 ) (3,748 ) Year Ended December 31, 2017 Foreign currency Provision for Total Beginning balance (3,315 ) (634 ) (3,949 ) Other comprehensive income (loss) before reclassifications – – – Reclassified from accumulated other comprehensive loss – – – Net current-period other comprehensive income (loss) 288 57 345 Ending balance (3,027 ) (577 ) (3,604 ) |
Note 17 - Total Sales (Tables)
Note 17 - Total Sales (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Revenue from External Customers by Geographic Areas [Table Text Block] | Primary geographical markets (€) 2018 2017 2016 Asia 14,119 13,461 10,427 France 11,577 10,573 9,606 United States 2,048 1,748 3,418 Others geographical areas 11,419 9,904 12,127 39,163 35,686 35,579 |
Disaggregation of Revenue [Table Text Block] | Timing of revenue recognition 2018 2017 2016 Products transferred at a point in time 31,373 28,760 29,842 Products and services transferred over time 7,790 6,927 5,737 39,163 35,686 35,579 |
Note 18 - Other Revenues (Table
Note 18 - Other Revenues (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Other Revenues [Table Text Block] | 2018 2017 2016 Licenses and others 19 60 32 Total 19 60 32 |
Note 19 - Costs of Sales (Table
Note 19 - Costs of Sales (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Costs of Sales [Table Text Block] | 2018 2017 2016 Direct costs of sales (13,683 ) (12,706 ) (11,161 ) Indirect costs of sales (8,583 ) (8,232 ) (8,039 ) Total costs of sales (22,266 ) (20,938 ) (19,200 ) |
Note 20 - Research and Develo_2
Note 20 - Research and Development Expenses (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Research and Development Expenses [Table Text Block] | 2018 2017 2016 Gross research and development expenses (4,863 ) (4,539 ) (4,577 ) Research Tax Credit 685 504 511 Grants 90 154 198 Net Research and development expenses (4,088 ) (3,881 ) (3,868 ) |
Note 21 - Financial Income, N_2
Note 21 - Financial Income, Net (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Interest Income and Interest Expense Disclosure [Table Text Block] | 2018 2017 2016 Interest income 19 18 21 Interest expense (111 ) (44 ) (57 ) Warrants exercised / forfeited 889 625 174 Changes in fair value of Financial Instrument (1) – 2,044 3,811 Total 797 2,643 3,949 |
Note 22 - Income Taxes (Tables)
Note 22 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | 2018 2017 2016 France 1,687 1,003 4,936 Other countries (1,667 ) (1,296 ) (492 ) Total 20 (293 ) 4,444 |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | 2018 2017 2016 Current income tax expense: France (163 ) (161 ) (323 ) Other countries (351 ) (373 ) (249 ) Sub-total current income tax expense (515 ) (534 ) (572 ) Deferred income tax (expense) benefit: France 2 (15 ) (2 ) Other countries 155 161 (30 ) Sub-total deferred income tax (expense) benefit 157 146 (32 ) Total (358 ) (388 ) (602 ) |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | December 31, 2018 2017 Net operating loss carry forwards 13,675 13,218 Elimination of intercompany profit in inventory 187 167 Elimination of intercompany profit in fixed assets 343 265 Provisions for retirement indemnities 488 566 Capital leases treated as operating leases for tax 10 (3 ) Other items 174 216 Total deferred tax assets 14,877 14,431 Total deferred tax liabilities – – Net deferred tax assets 14,877 14,431 Valuation allowance for deferred tax assets (14,553 ) (14,266 ) Deferred tax assets (liabilities), net of allowance 324 165 |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2018 2017 2016 Effective income / (loss) tax at French statutory tax rate (6 ) 98 (1,480 ) Income of foreign subsidiaries taxed at different tax rates (124 ) 64 109 Effect of net operating loss carry-forwards and valuation allowances (210 ) (1,530 ) 115 Non-taxable debt fair value variation 235 1,026 1,207 Permanent differences (392 ) 178 217 Effect of cancellation of intra-group positions 35 144 – French business tax included in income tax (CVAE) (161 ) (161 ) (152 ) Other 265 (207 ) (617 ) Effective income (loss) tax (358 ) (388 ) (602 ) |
Note 23 - Earnings (Loss) Per_2
Note 23 - Earnings (Loss) Per Share (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | December 31, December 31, December 31, Income (loss) available to common shareholders (in Euros) (€338,38)2 (€681,345) €3,842,201 Number of shares for the computation of basic EPS 28,997,866 28,961,928 27,823,313 Basic EPS (in Euros) (€0.01) (€0.02) €0.14 Effect of dilutive securities 347,500 581,915 1,542,270 Number of shares for the computation of diluted EPS 28,997,866 28,961,928 29,365,583 Diluted EPS income / (loss) (in Euros) (€0.01) (€0.02) €0.13 |
Note 25 - Fair Value of Finan_2
Note 25 - Fair Value of Financial Instruments (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Fair Value Measurement Inputs Level 1 [Table Text Block] | ASC 820 December 31, December 31, Assets: Cash and cash equivalents Level 1 19,464 20,004 Liabilities: Short-term borrowings Level 1 3,683 2,718 Long-Term Debt Level 1 1,830 1,217 Investor Warrants Level 3 – 840 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | All amounts in Investor Investor Investor Total Financial As of December 31, 2016 640 1,118 2,162 3,921 Warrants forfeited (see note 21) (1) (489 ) – – (489 ) Warrants exercises (see note 21) (1) (136 ) – – (136 ) FV adjustments (see note 21) (1) – (656 ) (1,388 ) (2,044 ) USD/EUR exchange impact (2) (16 ) (135 ) (262 ) (412 ) As of December 31, 2017 – 328 512 840 FV adjustments (see note 21) (1) – (345 ) (544 ) (889 ) USD/EUR exchange impact (2) – 17 32 49 As of December 31, 2018 – – – – |
Note 28 - Segment Information (
Note 28 - Segment Information (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] | 2018 2017 2016 Segment operating income (loss) (1,315 ) (2,027 ) 392 Financial income (expense), net 797 2,643 3,949 Foreign Currency exchange (losses) gains, net 538 (909 ) 103 Income tax (expense) credit (358 ) (388 ) (602 ) Consolidated net profit (loss) (338 ) (681 ) 3,842 |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | HIFU Division UDS Division Reconciling (1) Total consolidated 2018 Sales of goods 5,494 19,576 – 25,070 Sales of RPPs & leases 3,750 1,336 – 5,086 Sales of spare parts and services 1,780 7,227 – 9,007 Total sales 11,025 28,139 – 39,163 External other revenues 19 – – 19 Total revenues 11,044 28,139 39,183 Total COS (5,312 ) (16,954 ) – (22,266 ) Gross profit 5,732 11,185 – 16,917 R&D expenses (2,394 ) (1,694 ) – (4,088 ) Selling and marketing expenses (4,628 ) (5,923 ) – (10,551 ) G&A expenses (1,036 ) (1,311 ) (1,246 ) (3,593 ) Total expenses (8,057 ) (8,928 ) (1,246 ) (18,232 ) Operating income (loss) from operations (2,325 ) 2,257 (1,246 ) (1,315 ) Total Assets 13,648 29,849 5,243 48,740 Capital expenditures 1,154 775 – 1,928 Long-lived assets 2,855 5,158 – 8,013 Goodwill 645 1,767 – 2,412 HIFU Division UDS Division Reconciling (1) Total consolidated 2017 Sales of goods 4,232 18,348 – 22,580 Sales of RPPs & leases 3,800 1,295 – 5,095 Sales of spare parts and services 1,445 6,566 – 8,011 Total sales 9,477 26,209 – 35,686 External other revenues 36 24 – 60 Total revenues 9,513 26,233 35,746 Total COS (4,732 ) (16,207 ) – (20,938 ) Gross profit 4,782 10,026 – 14,808 R&D expenses (2,469 ) (1,413 ) – (3,881 ) Selling and marketing expenses (4,004 ) (5,521 ) – (9,526 ) G&A expenses (1,009 ) (1,057 ) (1,362 ) (3,428 ) Total expenses (7,482 ) (7,991 ) (1,362 ) (16,835 ) Operating income (loss) from operations (2,701 ) 2,035 (1,362 ) (2,027 ) Total Assets 11,333 27,803 7,761 46,897 Capital expenditures 1,190 928 – 2,118 Long-lived assets 2,804 4,278 – 7,082 Goodwill 645 1,767 – 2,412 HIFU Division UDS Division Reconciling (1) Total consolidated 2016 Sales of goods 9,382 14,664 – 24,045 Sales of RPPs & leases 3,547 1,359 – 4,906 Sales of spare parts and services 862 5,766 – 6,628 Total sales 13,791 21,789 – 35,579 External other revenues 28 4 – 32 Total revenues 13,819 21,792 35,611 Total COS (5,710 ) (13,490 ) – (19,200 ) Gross profit 8,109 8,302 – 16,411 R&D expenses (2,452 ) (1,416 ) – (3,868 ) Selling and marketing expenses (3,888 ) (4,968 ) – (8,856 ) G&A expenses (804 ) (1,177 ) (1,315 ) (3,296 ) Total expenses (7,144 ) (7,560 ) (1,315 ) (16,019 ) Operating income (loss) from operations 964 742 (1,315 ) 392 Total Assets 11,680 24,202 10,709 46,591 Capital expenditures 1,013 608 – 1,621 Long-lived assets 1,775 3,812 192 5,779 Goodwill 645 1,767 – 2,412 |
Note 29 - Valuation Accounts (T
Note 29 - Valuation Accounts (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Valuation Allowance for Impairment of Recognized Servicing Assets [Table Text Block] | Allowance for Allowance for Slow-moving Warranty Balance as of December 31, 2015 19,212 1,091 728 576 Charges to costs and expenses 238 103 121 319 Deductions: write-off and others (233 ) (46 ) (347 ) Balance as of December 31, 2016 19,450 960 803 548 Charges to costs and expenses 1,536 69 239 316 Deductions: write-off and others (6,720 ) – (319 ) (415 ) Balance as of December 31, 2017 14,266 1,029 723 449 Charges to costs and expenses 515 365 355 433 Deductions: write-off and others (228 ) 10 (104 ) (334 ) Balance as of December 31, 2018 14,553 1,404 974 548 |
Note 30 - Supplemental Disclo_2
Note 30 - Supplemental Disclosures of Cash Flow Information (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] | 2018 2017 2016 Income taxes paid (refunds received) 407 585 596 Interest paid 49 41 41 Interest received 12 7 4 Non-cash transactions: 2018 2017 2016 Capital lease obligations incurred 427 484 285 |
Note 1 - Summary of Significa_3
Note 1 - Summary of Significant Accounting Policies (Details Textual) - EUR (€) € in Thousands, shares in Thousands | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Jan. 01, 2019 | |
Product Warranty Expense | € 433 | € 316 | € 319 | ||
Advertising Expense | € 719 | € 672 | € 744 | ||
Class of Warrant or Right, Outstanding | 0 | ||||
Subsequent Event [Member] | Accounting Standards Update 2016-02 [Member] | |||||
Operating Lease, Right-of-Use Asset | € 2,900 | ||||
Operating Lease, Liability, Total | € 2,900 | ||||
Minimum [Member] | |||||
Revenue from Contract with Customer, Customer Payment Period | 30 days | ||||
Standard Product Warranty Period | 1 year | 1 year | |||
Maximum [Member] | |||||
Revenue from Contract with Customer, Customer Payment Period | 90 days | ||||
Standard Product Warranty Period | 2 years | 2 years | |||
Maximum [Member] | Devices Leased Under RPPs and Devices Subject to Sale and Leaseback Transactions [Member] | |||||
Property, Plant and Equipment, Useful Life | 7 years |
Note 1 - Summary of Significa_4
Note 1 - Summary of Significant Accounting Policies - Estimated Useful Life of Property and Equipment (Details) | 12 Months Ended |
Dec. 31, 2018 | |
Leasehold Improvements [Member] | |
Estimated useful life (Year) | 10 years |
Equipment [Member] | Minimum [Member] | |
Estimated useful life (Year) | 3 years |
Equipment [Member] | Maximum [Member] | |
Estimated useful life (Year) | 10 years |
Furniture, Fixtures, Fittings, and Other [Member] | Minimum [Member] | |
Estimated useful life (Year) | 2 years |
Furniture, Fixtures, Fittings, and Other [Member] | Maximum [Member] | |
Estimated useful life (Year) | 10 years |
Note 1 - Summary of Significa_5
Note 1 - Summary of Significant Accounting Policies - Estimated Useful Life of Intangible Assets (Details) | 12 Months Ended |
Dec. 31, 2018 | |
Patents [Member] | |
Finite intangible assets, useful life (Year) | 5 years |
SAP Licenses [Member] | |
Finite intangible assets, useful life (Year) | 10 years |
Other Licenses [Member] | |
Finite intangible assets, useful life (Year) | 5 years |
Trademarks and Trade Names [Member] | |
Finite intangible assets, useful life (Year) | 7 years |
Note 2 - Cash Equivalents - Sch
Note 2 - Cash Equivalents - Schedule of Cash Equivalents and Short Term Investments (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Total cash and cash equivalents | € 19,464 | € 20,004 | € 21,989 | € 13,578 |
Short term investments | ||||
Total cash and cash equivalents, and short term investments | € 19,464 | € 20,004 |
Note 3 - Trade Accounts and N_3
Note 3 - Trade Accounts and Notes Receivable, Net (Details Textual) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Provision for Doubtful Accounts | € 362 | € 107 | € 18 |
Note 3 - Trade Accounts and N_4
Note 3 - Trade Accounts and Notes Receivable, Net - Schedule of Accounts, Notes, Loans and Financing Receivable (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Trade accounts receivable | € 12,907 | € 12,202 |
Notes receivable | 408 | 181 |
Less: allowance for doubtful accounts | (1,405) | (1,029) |
Total | 11,910 | 11,354 |
Less current portion | (11,884) | (11,277) |
Net Trade accounts and notes receivable, non-current | € 26 | € 77 |
Note 3 - Trade Accounts and N_5
Note 3 - Trade Accounts and Notes Receivable, Net - Schedule of Long Term Payments Receivable (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Total minimum payments | € 26 | € 77 |
Sales Type Leases [Member] | ||
2019 | 42 | |
2020 | 18 | |
2021 | 8 | |
2022 | ||
2022 | ||
Total minimum payments | € 70 |
Note 4 - Other Receivables - Sc
Note 4 - Other Receivables - Schedule of Other Receivables (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Research and development tax credit receivable from the French State | € 685 | € 560 |
Value-added taxes receivable | 390 | 216 |
Other receivables from Government and public authorities | 233 | 238 |
Others | 126 | 52 |
Total | € 1,434 | € 1,066 |
Note 5 - Inventories (Details T
Note 5 - Inventories (Details Textual) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Inventory Write-down | € 227 | € 41 | € 55 |
Note 5 - Inventories - Schedule
Note 5 - Inventories - Schedule of Inventories (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Components, spare parts | € 3,496 | € 3,909 |
Work-in-progress | 576 | 729 |
Finished goods – own manufactured products | 2,672 | 1,167 |
Finished goods – distribution products | 1,442 | 1,656 |
Total gross inventories | 8,186 | 7,461 |
Less: allowance for slow-moving inventory and net realizable value | (974) | (722) |
Total | € 7,212 | € 6,739 |
Note 6 - Other Assets - Schedul
Note 6 - Other Assets - Schedule of Other Assets (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Prepaid expenses, current portion | € 382 | € 489 |
Total | € 382 | € 489 |
Note 7 - Property and Equipme_3
Note 7 - Property and Equipment, Net (Details Textual) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Depreciation, Depletion and Amortization, Nonproduction, Total | € 1,367 | € 1,153 | € 843 |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance | 8,534 | 7,672 | |
Assets Held under Capital Leases [Member] | |||
Depreciation, Depletion and Amortization, Nonproduction, Total | 386 | 218 | 164 |
Capital Leased Assets, Gross, Total | 2,704 | 2,081 | |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance | 2,291 | 2,018 | |
Vehicles, Office and IT Equipment Held Under Capital Leases [Member] | |||
Capital Leased Assets, Gross, Total | 1,423 | 981 | |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance | 619 | 528 | |
Equipment Leased to Other Party [Member] | |||
Depreciation, Depletion and Amortization, Nonproduction, Total | 51 | 24 | € 2 |
Capital Leased Assets, Gross, Total | 351 | 474 | |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance | € 72 | € 27 |
Note 7 - Property and Equipme_4
Note 7 - Property and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Property and equipment, gross | € 12,742 | € 11,354 |
Less: accumulated depreciation and amortization | (8,534) | (7,672) |
Total | 4,208 | 3,682 |
Equipment [Member] | ||
Property and equipment, gross | 8,677 | 7,588 |
Furniture and Fixtures [Member] | ||
Property and equipment, gross | € 4,064 | € 3,766 |
Note 8 - Goodwill and Intangi_3
Note 8 - Goodwill and Intangible Assets (Details Textual) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018EUR (€) | Dec. 31, 2017EUR (€) | Dec. 31, 2016EUR (€) | |
Goodwill, Ending Balance | € 2,412 | € 2,412 | |
Number of Reporting Units | 2 | ||
Goodwill, Impairment Loss | € 0 | ||
Amortization of Intangible Assets, Total | 110 | € 74 | € 42 |
Urology Devices and Services (UDS) [Member] | |||
Goodwill, Ending Balance | 1,767 | ||
High Intensity Focused Ultrasound (HIFU) [Member] | |||
Goodwill, Ending Balance | € 645 |
Note 8 - Goodwill and Intangi_4
Note 8 - Goodwill and Intangible Assets - Schedule of Finite-lived Intangible Assets (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Finite-lived, intangible assets, gross | € 2,577 | € 2,118 |
Finite-lived, intangible assets, accumulated amortization | (1,730) | (1,591) |
Total | 847 | 527 |
Licensing Agreements [Member] | ||
Finite-lived, intangible assets, gross | 1,431 | 993 |
Finite-lived, intangible assets, accumulated amortization | (587) | (477) |
Trademarks and Trade Names [Member] | ||
Finite-lived, intangible assets, gross | 414 | 393 |
Finite-lived, intangible assets, accumulated amortization | (411) | (383) |
Patents [Member] | ||
Finite-lived, intangible assets, gross | 412 | 412 |
Finite-lived, intangible assets, accumulated amortization | (412) | (411) |
Organization Costs [Member] | ||
Finite-lived, intangible assets, gross | 320 | 320 |
Finite-lived, intangible assets, accumulated amortization | € (320) | € (320) |
Note 8 - Goodwill and Intangi_5
Note 8 - Goodwill and Intangible Assets - Schedule of Finite-lived Intangible Assets, Future Amortization Expense (Details) € in Thousands | Dec. 31, 2018EUR (€) |
2019 | € 97 |
2020 | 89 |
2021 | 87 |
2022 | 85 |
2023 | 83 |
Total | € 441 |
Note 9 - Trade Accounts and N_3
Note 9 - Trade Accounts and Notes Payable - Schedule of Trade Accounts and Notes Payable (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Trade accounts payable | € 6,286 | € 6,220 |
Notes payable | 11 | 90 |
Total | € 6,297 | € 6,310 |
Note 10 - Deferred Revenues - S
Note 10 - Deferred Revenues - Summary of Deferred Revenues (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Deferred revenues, total | € 2,902 | € 2,857 |
Less long term portion | (973) | (562) |
Deferred revenues, current portion | 1,929 | 2,295 |
Maintenance [Member] | ||
Deferred revenues, total | 1,246 | 1,497 |
RPP [Member] | ||
Deferred revenues, total | 339 | 405 |
Sale of Devices [Member] | ||
Deferred revenues, total | 289 | 218 |
Extension of Warranty [Member] | ||
Deferred revenues, total | 855 | 676 |
Research and Development Grants [Member] | ||
Deferred revenues, total | € 173 | € 61 |
Note 10 - Deferred Revenues - D
Note 10 - Deferred Revenues - Deferred Revenue Recognition Period (Details) € in Thousands | Dec. 31, 2018EUR (€) |
Extension of Warranty [Member] | |
Revenue, remaining performance obligation, amount | € 855 |
Note 10 - Deferred Revenues -_2
Note 10 - Deferred Revenues - Deferred Revenue Recognition Period 2 (Details) - Extension of Warranty [Member] € in Thousands | Dec. 31, 2018EUR (€) |
Revenue, remaining performance obligation, amount | € 855 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | |
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year) | 1 year |
Revenue, remaining performance obligation, amount | € 167 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | |
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year) | 1 year |
Revenue, remaining performance obligation, amount | € 264 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | |
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year) | 1 year |
Revenue, remaining performance obligation, amount | € 218 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | |
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year) | 1 year |
Revenue, remaining performance obligation, amount | € 162 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | |
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year) | 1 year |
Revenue, remaining performance obligation, amount | € 44 |
Note 10 - Deferred Revenues - C
Note 10 - Deferred Revenues - Change in Deferred Revenue on Extension of Warranty (Details) € in Thousands | 12 Months Ended |
Dec. 31, 2018EUR (€) | |
Beginning balance | € 2,857 |
Ending balance | 2,902 |
Extension of Warranty [Member] | |
Beginning balance | 676 |
New extension of warranty | 331 |
Recognition of revenue | (152) |
Ending balance | € 855 |
Note 11 - Other Accrued Liabi_3
Note 11 - Other Accrued Liabilities (Details Textual) | Dec. 31, 2018 |
Conditional Advances, Interest Rate, Percentage | 1.44% |
Note 11 - Other Accrued Liabi_4
Note 11 - Other Accrued Liabilities - Schedule of Other Accrued Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Retirement indemnities | € 2,287 | € 2,076 | |
Provision for warranty costs | 547 | 449 | € 548 |
Accruals for payroll and associated taxes | 680 | 611 | |
Conditional government advances | 1,039 | 1,039 | |
Value added tax payable | 327 | 125 | |
Advances received from customers | 115 | 108 | |
Provision for Asset Retirement Obligation (Japan) | 118 | 100 | |
Others | 411 | 360 | |
Total | 5,923 | 5,217 | |
Less non-current portion | (3,800) | (3,681) | |
Other accrued liabilities | 2,122 | 1,536 | |
ITALY | |||
Provision for employee termination indemnities | 369 | 349 | |
KOREA, REPUBLIC OF | |||
Provision for employee termination indemnities | € 30 |
Note 11 - Other Accrued Liabi_5
Note 11 - Other Accrued Liabilities - Conditional Advances (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
2019 | ||
2020 | ||
2021 | ||
2022 | 203 | |
2023 and thereafter | 836 | |
Total | € 1,039 | € 1,039 |
Note 11 - Other Accrued Liabi_6
Note 11 - Other Accrued Liabilities - Schedule of Changes in Warranty Costs Provision (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Beginning of year | € 449 | € 548 |
Amount used during the year | (335) | (415) |
New warranty expenses | 433 | 316 |
End of year | 547 | 449 |
Less current portion | (356) | (265) |
Long term portion | € 191 | € 184 |
Note 12 - Lease Obligations (De
Note 12 - Lease Obligations (Details Textual) € in Thousands, $ in Thousands | 12 Months Ended | ||||
Dec. 31, 2018EUR (€) | Dec. 31, 2017EUR (€) | Dec. 31, 2016EUR (€) | Dec. 31, 2018USD ($) | Dec. 31, 2018EUR (€) | |
Interest Expense, Lessee, Assets under Capital Lease | € 21 | € 13 | € 18 | ||
Operating Leases, Rent Expense, Net, Total | € 1,002 | € 904 | € 841 | ||
FRANCE | |||||
Lessee, Operating Lease, Term of Contract | 10 years | 10 years | |||
Medical Devices [Member] | |||||
Capital Lease Obligations, Total | € 432 | ||||
Vehicles and Other IT Equipment [Member] | |||||
Capital Lease Obligations, Total | $ | $ 802 |
Note 12 - Lease Obligations - S
Note 12 - Lease Obligations - Schedule of Future Minimum Lease Payments for Capital Leases (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
2019 | € 401 | |
2020 | 361 | |
2021 | 252 | |
2022 | 170 | |
2023 and thereafter | 89 | |
Total minimum lease payments | 1,273 | |
Less: amount representing interest | (39) | |
Present value of minimum lease payments | 1,234 | |
Less: current portion | (383) | € (255) |
Capital lease obligations, non-current | € 852 | € 528 |
Note 12 - Lease Obligations -_2
Note 12 - Lease Obligations - Schedule of Future Minimum Rental Payments for Operating Leases (Details) € in Thousands | Dec. 31, 2018EUR (€) |
FRANCE | |
2019 | € 329 |
2020 | 329 |
2021 | 329 |
2022 | 329 |
2023 and thereafter | 822 |
Total | 2,138 |
JAPAN | |
2019 | 227 |
2020 | 167 |
2021 | 132 |
2022 | 39 |
2023 and thereafter | |
Total | 565 |
UNITED STATES | |
2019 | 45 |
2020 | 45 |
2021 | 4 |
2022 | |
2023 and thereafter | |
Total | 94 |
ITALY | |
2019 | 37 |
2020 | 37 |
2021 | 37 |
2022 | 25 |
2023 and thereafter | |
Total | € 135 |
Note 13 - Short-term Borrowin_2
Note 13 - Short-term Borrowings (Details Textual) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Short-term Debt, Total | € 3,683 | € 2,718 |
Factored Account Receivables [Member] | ||
Short-term Debt, Total | € 3,683 | € 2,718 |
Note 14 - Long Term Debt and _3
Note 14 - Long Term Debt and Financial Instruments Carried at Fair Value (Details Textual) $ / shares in Units, € in Thousands, $ in Thousands | Apr. 14, 2016USD ($)$ / sharesshares | Apr. 14, 2016EUR (€)shares | May 28, 2013USD ($)$ / sharesshares | May 28, 2013EUR (€)shares | Dec. 31, 2018EUR (€) | Dec. 31, 2017EUR (€) | Mar. 28, 2018shares |
American Depository Shares (ADS) [Member] | Private Placement [Member] | |||||||
Stock Issued During Period, Shares, New Issues | 3,283,284 | 3,283,284 | 3,000,000 | 3,000,000 | |||
Shares Issued, Price Per Share | $ / shares | $ 3.50 | $ 4 | |||||
Proceeds from Issuance of Private Placement | $ 11,500 | € 10,200 | $ 12,000 | € 9,270 | |||
American Depository Shares (ADS) [Member] | Private Placement [Member] | Additional Paid-in Capital [Member] | |||||||
Proceeds from Issuance of Private Placement | 7,913 | 7,006 | 8,183 | 6,320 | |||
American Depository Shares (ADS) [Member] | Private Placement [Member] | Investor and Placement Agent Warrants Payable [Member] | |||||||
Proceeds from Issuance of Private Placement | $ 3,578 | € 3,168 | $ 3,817 | € 2,950 | |||
May 2013 Investor Warrants [Member] | American Depository Shares (ADS) [Member] | Private Placement [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,500,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 4.25 | ||||||
May 2013 Placement Agent Warrants [Member] | American Depository Shares (ADS) [Member] | Private Placement [Member] | H.C. Wainwright & Co., LLC [Member] | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 5 | ||||||
April 2016 Investor Warrants [Member] | American Depository Shares (ADS) [Member] | Private Placement [Member] | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 4.50 | ||||||
Maximum [Member] | March 2012 Investor Warrants [member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,406,250 | ||||||
Maximum [Member] | March 2012 Placement Agent Warrants [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 168,750 | ||||||
Maximum [Member] | April 2016 Investor Warrants [Member] | American Depository Shares (ADS) [Member] | Private Placement [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 3,283,284 | ||||||
Loans Payable [Member] | GERMANY | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member] | |||||||
Debt Instrument, Collateral Amount | € | € 450 | ||||||
Loans Payable [Member] | GERMANY | Urology Devices and Services (UDS) Equipment [Member] | |||||||
Debt Instrument, Collateral Amount | € | 136 | ||||||
Loans Payable [Member] | GERMANY | High Intensity Focused Ultrasound (HIFU) Equipment 2 [Member] | |||||||
Debt Instrument, Collateral Amount | € | 438 | ||||||
Loans Payable [Member] | ITALY | |||||||
Debt Instrument, Face Amount | € | € 242 | € 242 | |||||
Loans Payable [Member] | ITALY | Euribor 1 Month [Member] | |||||||
Debt Instrument, Basis Spread on Variable Rate | 4.50% | 4.50% |
Note 14 - Long Term Debt and _4
Note 14 - Long Term Debt and Financial Instruments Carried at Fair Value - Schedule of Long Term Debt (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Long term debt | € 1,830 | € 1,217 |
Less current portion | (491) | (383) |
Total long-term portion | 1,339 | 834 |
FRANCE | ||
Long term debt | 526 | 700 |
JAPAN | ||
Long term debt | 628 | 40 |
GERMANY | ||
Long term debt | 632 | 399 |
ITALY | ||
Long term debt | 27 | 78 |
Malaysia 1 [Member] | ||
Long term debt | € 17 |
Note 14 - Long Term Debt and _5
Note 14 - Long Term Debt and Financial Instruments Carried at Fair Value - Long-term Debt (Details) | 12 Months Ended | |||
Dec. 31, 2018MYR (RM) | Dec. 31, 2017JPY (¥) | Dec. 31, 2018EUR (€) | Dec. 31, 2018JPY (¥) | |
JAPAN | EDAP Technomed Co Ltd. [Member] | Loan One [Member] | ||||
Debt Instrument, Face Amount | ¥ | ¥ 80,000,000 | |||
Maturation | Nov. 30, 2025 | |||
Interest rate | 1.98% | 1.98% | 1.98% | |
Frequency of principal payments | Monthly instalment | |||
JAPAN | EDAP Technomed Co Ltd. [Member] | Loan Two [Member] | ||||
Debt Instrument, Face Amount | ¥ | ¥ 55,000,000 | |||
Maturation | Jun. 30, 2018 | |||
Interest rate | 1.80% | |||
Frequency of principal payments | Monthly instalment | |||
JAPAN | EDAP Technomed Co Ltd. [Member] | Loan Three [Member] | ||||
Debt Instrument, Face Amount | ¥ | ¥ 10,000,000 | |||
Maturation | Jun. 30, 2018 | |||
Interest rate | 2.10% | |||
Frequency of principal payments | Monthly instalment | |||
GERMANY | EDAP TMS GMBH [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member] | ||||
Debt Instrument, Face Amount | € 450,000 | |||
Maturation | Nov. 30, 2020 | |||
Interest rate | 2.49% | 2.49% | 2.49% | |
Frequency of principal payments | Monthly instalment | |||
GERMANY | EDAP TMS GMBH [Member] | Urology Devices and Services (UDS) Equipment [Member] | ||||
Debt Instrument, Face Amount | € 136,500 | |||
Maturation | Dec. 31, 2022 | |||
Interest rate | 2.25% | 2.25% | 2.25% | |
Frequency of principal payments | Monthly instalment | |||
GERMANY | EDAP TMS GMBH [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 2 [Member] | ||||
Debt Instrument, Face Amount | € 400,000 | |||
Maturation | Apr. 30, 2023 | |||
Interest rate | 2.40% | 2.40% | 2.40% | |
Frequency of principal payments | Monthly instalment | |||
FRANCE | EDAP TMS France [Member] | Loan One [Member] | ||||
Debt Instrument, Face Amount | € 700,000 | |||
Maturation | Oct. 16, 2021 | |||
Interest rate | 0.40% | 0.40% | 0.40% | |
Frequency of principal payments | Quarterly instalment | |||
Malaysia 1 [Member] | EDAP Technomed Sdn Bdh [Member] | ||||
Debt Instrument, Face Amount | RM | RM 90,000 | |||
Maturation | Jul. 31, 2022 | |||
Interest rate | 4.64% | 4.64% | 4.64% | |
Frequency of principal payments | Monthly instalment |
Note 14 - Long Term Debt and _6
Note 14 - Long Term Debt and Financial Instruments Carried at Fair Value - Schedule of Financial Instruments Carried at Fair Value (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Less current portion | € (840) | |
Total long-term portion | ||
Investor Warrants [Member] | ||
Warrants | 840 | |
Warrant [Member] | ||
Warrants | 840 | |
Less current portion | (840) | |
Total long-term portion |
Note 14 - Long Term Debt and _7
Note 14 - Long Term Debt and Financial Instruments Carried at Fair Value - Valuation Model of Warrants (Details) $ / shares in Units, € in Thousands, $ in Thousands | Dec. 31, 2018USD ($)$ / shares | Dec. 31, 2018EUR (€) | Dec. 31, 2017USD ($)$ / shares | Dec. 31, 2017EUR (€) | Apr. 14, 2016USD ($)$ / shares | Apr. 14, 2016EUR (€) | Mar. 28, 2012USD ($)$ / shares | Mar. 28, 2012EUR (€) |
May 2013 Investor Warrants [Member] | ||||||||
Unit fair value (in dollars per share) | $ 0.26 | $ 2.35 | ||||||
Total fair value | $ 392 | € 328 | $ 3,525 | € 2,725 | ||||
April 2016 Investor Warrants [Member] | ||||||||
Unit fair value (in dollars per share) | $ 0.19 | $ 1.09 | ||||||
Total fair value | $ 614 | € 512 | $ 3,579 | € 3,168 | ||||
Measurement Input, Share Price [Member] | May 2013 Investor Warrants [Member] | ||||||||
Warrants, measurement input | 2.87 | 2.87 | 3.96 | 3.96 | ||||
Measurement Input, Share Price [Member] | April 2016 Investor Warrants [Member] | ||||||||
Warrants, measurement input | 2.87 | 2.87 | 3.64 | 3.64 | ||||
Measurement Input, Exercise Price [Member] | May 2013 Investor Warrants [Member] | ||||||||
Warrants, measurement input | 4.25 | 4.25 | 4.25 | 4.25 | ||||
Measurement Input, Exercise Price [Member] | April 2016 Investor Warrants [Member] | ||||||||
Warrants, measurement input | 4.5 | 4.5 | 4.5 | 4.5 | ||||
Measurement Input, Risk Free Interest Rate [Member] | May 2013 Investor Warrants [Member] | ||||||||
Warrants, measurement input | 0 | 0 | 1.07 | 1.07 | ||||
Measurement Input, Risk Free Interest Rate [Member] | April 2016 Investor Warrants [Member] | ||||||||
Warrants, measurement input | 0 | 0 | 0 | 0 | ||||
Measurement Input, Price Volatility [Member] | May 2013 Investor Warrants [Member] | ||||||||
Warrants, measurement input | 57.4 | 57.4 | 71 | 71 | ||||
Measurement Input, Price Volatility [Member] | April 2016 Investor Warrants [Member] | ||||||||
Warrants, measurement input | 0.574 | 0.574 | 0.602 | 0.602 | ||||
Measurement Input, Expected Dividend Rate [Member] | May 2013 Investor Warrants [Member] | ||||||||
Warrants, measurement input | 0 | 0 | 0 | 0 | ||||
Measurement Input, Expected Dividend Rate [Member] | April 2016 Investor Warrants [Member] | ||||||||
Warrants, measurement input | 0 | 0 | 0 | 0 |
Note 14 - Long Term Debt and _8
Note 14 - Long Term Debt and Financial Instruments Carried at Fair Value - Valuation Model of Warrants (Details) (Parentheticals) | Dec. 31, 2018 | Dec. 31, 2017 | Apr. 14, 2016 | Mar. 28, 2012 |
May 2013 Investor Warrants [Member] | ||||
Risk free interest rate, period (Year) | 5 years 182 days | 5 years 182 days | 5 years 182 days | |
April 2016 Investor Warrants [Member] | ||||
Risk free interest rate, period (Year) | 2 years 182 days | 2 years 182 days | 2 years 182 days |
Note 14 - Long Term Debt and _9
Note 14 - Long Term Debt and Financial Instruments Carried at Fair Value - Schedule Of Long-term Debt and Financial Instruments Maturities (Details) € in Thousands | Dec. 31, 2018EUR (€) |
2019 | € 491 |
2020 | 460 |
2021 | 381 |
2022 | 205 |
2023 and thereafter | 293 |
Total | € 1,830 |
Note 15 - Other Long-term Lia_3
Note 15 - Other Long-term Liabilities (Details Textual) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Defined Benefit Retirement Indemnity Plans, France [Member] | ||
Defined Benefit Plan, Accumulated Benefit Obligation | € 692 | € 627 |
Defined Benefit Plan, Expected Amortization, Next Fiscal Year, Total | 4 | |
Defined Benefit Retirement Indemnity Plans, Japan [Member] | ||
Defined Benefit Plan, Accumulated Benefit Obligation | 960 | € 872 |
Defined Benefit Plan, Expected Amortization, Next Fiscal Year, Total | € 26 |
Note 15 - Other Long-term Lia_4
Note 15 - Other Long-term Liabilities - Other Long-term Liabilities (Details) € in Thousands, $ in Thousands | Dec. 31, 2018USD ($) | Dec. 31, 2018EUR (€) | Dec. 31, 2017USD ($) | Dec. 31, 2017EUR (€) |
Provision for retirement indemnities (Japan & France), less current portion | € 2,222 | € 2,008 | ||
Provision for Asset Retirement Obligation (Japan) less current portion | 118 | 101 | ||
Long term portion | 191 | 184 | ||
Conditional government advances, less current portion | 1,039 | 1,039 | ||
Accrued interest less current portion | 30 | |||
Total | 3,800 | 3,681 | ||
ITALY | ||||
Provision for employee termination indemnities, less current portion | € 170 | € 349 | ||
KOREA, REPUBLIC OF | ||||
Provision for employee termination indemnities, less current portion | $ | $ 30 |
Note 15 - Other Long-term Lia_5
Note 15 - Other Long-term Liabilities - Assumptions (Details) | Dec. 31, 2018 | Dec. 31, 2017 |
Defined Benefit Retirement Indemnity Plans, France [Member] | ||
Discount rate | 1.60% | 1.60% |
Salary increase | 2.50% | 2.50% |
Retirement age | 65 | 65 |
Average retirement remaining service period | 24 | 24 |
Defined Benefit Retirement Indemnity Plans, Japan [Member] | ||
Discount rate | 0.50% | 0.50% |
Salary increase | 2.50% | 2.50% |
Retirement age | 60 | 60 |
Average retirement remaining service period | 14 | 14 |
Note 15 - Other Long-term Lia_6
Note 15 - Other Long-term Liabilities - Provision Presentation According to ASC 715 (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Defined Benefit Retirement Indemnity Plans, France [Member] | |||
Non-current liabilities | € 966 | € 867 | |
Current liabilities | 10 | 27 | |
Accumulated other comprehensive income (loss) | (161) | (165) | |
Total | 815 | 729 | € 672 |
Defined Benefit Retirement Indemnity Plans, Japan [Member] | |||
Non-current liabilities | 1,255 | 1,141 | |
Current liabilities | 55 | 40 | |
Accumulated other comprehensive income (loss) | (416) | (412) | |
Total | € 895 | € 769 | € 698 |
Note 15 - Other Long-term Lia_7
Note 15 - Other Long-term Liabilities - Reconciliation of Pension Cost Components (Details) - EUR (€) € in Thousands | 12 Months Ended | |||||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | ||||
Defined Benefit Retirement Indemnity Plans, France [Member] | ||||||
Benefit obligations at beginning of year | € 895 | [1] | € 842 | [1] | € 694 | |
Service cost | 67 | 66 | 45 | |||
Interest cost | 14 | 13 | 15 | |||
Actuarial (gain) / loss | 88 | |||||
Amortization of net prior service cost | 1 | 1 | ||||
Benefits paid | (27) | |||||
Benefit obligations at end of year | [1] | 976 | 895 | 842 | ||
Unrecognized actuarial (gain) loss | [2] | 141 | 144 | 147 | ||
Unrecognized prior service cost | [2] | 20 | 22 | 23 | ||
Accrued pension cost | 815 | 729 | 672 | |||
Defined Benefit Retirement Indemnity Plans, Japan [Member] | ||||||
Benefit obligations at beginning of year | 1,182 | [3] | 1,162 | [3] | 906 | |
Service cost | 131 | 118 | 81 | |||
Interest cost | 6 | 6 | 10 | |||
Actuarial (gain) / loss | (12) | 147 | ||||
Benefits paid | (94) | (17) | (38) | |||
Benefit obligations at end of year | [3] | 1,311 | 1,182 | 1,162 | ||
Unrecognized actuarial (gain) loss | [4] | 416 | 412 | 464 | ||
Unrecognized prior service cost | [4] | |||||
Accrued pension cost | 895 | 769 | 698 | |||
Amortization of net loss | 26 | 24 | 16 | |||
Exchange rate impact | € (60) | € (99) | € 40 | |||
[1] | The accumulated benefit obligation was 692 thousand Euros and 627 thousand Euros at December 31, 2018 and 2017 respectively. | |||||
[2] | The amount in accumulated other comprehensive income (loss) to be recognised as components of net periodic benefit costs in 2019 is 4 thousand Euros. | |||||
[3] | The accumulated benefit obligation was 960 thousand Euros and 872 thousand Euros at December 31, 2018 and 2017, respectively. | |||||
[4] | The amount in accumulated other comprehensive income (loss) to be recognised as components of net periodic benefit costs in 2019 is 26 thousand Euros. |
Note 15 - Other Long-term Lia_8
Note 15 - Other Long-term Liabilities - Expected Benefit Payments (Details) € in Thousands | Dec. 31, 2018EUR (€) |
Defined Benefit Retirement Indemnity Plans, France [Member] | |
2018 | € 10 |
2019 | |
2020 | 86 |
2021 | |
2022 | 107 |
2023-2027 | 277 |
Defined Benefit Retirement Indemnity Plans, Japan [Member] | |
2018 | 55 |
2019 | 6 |
2020 | 55 |
2021 | 75 |
2022 | 96 |
2023-2027 | € 743 |
Note 16 - Shareholders' Equit_2
Note 16 - Shareholders' Equity (Details Textual) - EUR (€) | Aug. 29, 2018 | Apr. 25, 2017 | Apr. 26, 2016 | Jan. 18, 2013 | Jun. 25, 2010 | Jun. 24, 2010 | Jul. 31, 2001 | Dec. 31, 1998 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2013 | Feb. 18, 2016 | Dec. 31, 2015 | Dec. 19, 2012 | May 22, 2007 |
Common Stock, Shares, Issued, Total | 29,368,394 | 29,368,394 | ||||||||||||||
Common Stock, Par or Stated Value Per Share | € 0.13 | € 0.13 | ||||||||||||||
Common Stock, Shares, Outstanding, Ending Balance | 28,997,866 | 28,997,866 | ||||||||||||||
Statutory Retained Earnings (Statutory Accumulated Deficit) | € (15,011,000) | |||||||||||||||
Treasury Stock, Shares, Ending Balance | 370,528 | 370,528 | ||||||||||||||
Treasury Stock, Shares, Acquired | 180,290 | 190,238 | ||||||||||||||
Treasury Stock, Value, Acquired, Par Value Method | € 493,000 | € 649,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 165,000 | |||||||||||||||
Share Price | € 1.85 | |||||||||||||||
The 2010 Plan [Member] | ||||||||||||||||
Common Stock, Shares Subscribed but Unissued | 229,100 | |||||||||||||||
The 2012 Plan [Member] | ||||||||||||||||
Common Stock, Shares Subscribed but Unissued | 500,000 | |||||||||||||||
The 2016 Plan [Member] | ||||||||||||||||
Common Stock, Shares Subscribed but Unissued | 1,000,000 | |||||||||||||||
Employee Stock Option [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 165,000 | 260,000 | 575,000 | |||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | € 2.65 | € 2.39 | € 3.22 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 1,347,600 | 1,207,600 | 1,427,438 | 917,188 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 772,600 | 598,850 | 774,938 | |||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | € 352,000 | |||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 3 years 240 days | |||||||||||||||
Employee Stock Option [Member] | The 2007 Plan [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 600,000 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 95,912 | |||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | € 1.88 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 50,000 | |||||||||||||||
Employee Stock Option [Member] | The 2007 Plan [Member] | Minimum [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 1 year | |||||||||||||||
Employee Stock Option [Member] | The 2007 Plan [Member] | Maximum [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | |||||||||||||||
Employee Stock Option [Member] | The 2010 Plan [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 229,100 | |||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | € 2.38 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 120,100 | |||||||||||||||
Employee Stock Option [Member] | The 2010 Plan [Member] | Minimum [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 1 year | |||||||||||||||
Employee Stock Option [Member] | The 2010 Plan [Member] | Maximum [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | |||||||||||||||
Employee Stock Option [Member] | The 2012 Plan [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 500,000 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 500,000 | |||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | € 1.91 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 297,500 | |||||||||||||||
Stock Granted, Value, Share-based Compensation, Gross | € 660,000 | |||||||||||||||
Allocated Share-based Compensation Expense, Total | € 0 | € 2,000 | € 29,000 | |||||||||||||
Employee Stock Option [Member] | The 2012 Plan [Member] | Minimum [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 1 year | |||||||||||||||
Employee Stock Option [Member] | The 2012 Plan [Member] | Maximum [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | |||||||||||||||
Employee Stock Option [Member] | The 2016 Plan [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 1,000,000 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 165,000 | 260,000 | 575,000 | |||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | € 2.65 | € 2.39 | € 3.22 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | 10 years | 10 years | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 880,000 | |||||||||||||||
Stock Granted, Value, Share-based Compensation, Gross | € 219,000 | 335,000 | 960,000 | |||||||||||||
Allocated Share-based Compensation Expense, Total | € 289,000 | € 380,000 | € 331,000 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 305,000 | |||||||||||||||
Employee Stock Option [Member] | The 2016 Plan [Member] | Minimum [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 1 year | 1 year | 1 year | |||||||||||||
Employee Stock Option [Member] | The 2016 Plan [Member] | Maximum [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | 4 years | 4 years | |||||||||||||
The 2007 Plan [Member] | ||||||||||||||||
Common Stock, Shares Subscribed but Unissued | 600,000 | |||||||||||||||
Treasury Stock, Held for Purchase for Option Holder Exercises [Member] | ||||||||||||||||
Treasury Stock, Shares, Ending Balance | 120,100 | |||||||||||||||
Treasury Stock, Reissuance Price Per Share | € 2.38 |
Note 16 - Shareholders' Equit_3
Note 16 - Shareholders' Equity - Stock Option Assumptions (Details) - € / shares | 12 Months Ended | |||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | ||
Weighted-average expected life (years) (Year) | 6 years 91 days | 6 years 91 days | 6 years 91 days | |
Expected volatility rates(1) | [1] | 52.60% | 57.40% | 60.60% |
Expected dividend yield | 0.00% | 0.00% | 0.00% | |
Risk-free interest rate | 0.18% | 0.02% | 0.01% | |
Weighted-average exercise price (€) (in EUR per share) | € 2.65 | € 2.39 | € 3.22 | |
Non-vested options granted, weighted average grant-date fair value (in EUR per share) | € 1.33 | € 1.29 | € 1.67 | |
[1] | Historical volatility calculated over 10 years. |
Note 16 - Shareholders' Equit_4
Note 16 - Shareholders' Equity - Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) - € / shares | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Non-vested options granted (in shares) | 165,000 | ||
Employee Stock Option [Member] | |||
Outstanding - number (in shares) | 1,207,600 | 1,427,438 | 917,188 |
Outstanding - Weighted average exercise price (in EUR per share) | € 2.61 | € 2.94 | € 2.79 |
Non-vested options granted (in shares) | 165,000 | 260,000 | 575,000 |
Granted - Weighted average exercise price (in EUR per share) | € 2.65 | € 2.39 | € 3.22 |
Exercised - number (in shares) | (60,000) | ||
Exercised - Weighted average exercise price (in EUR per share) | € 1.91 | ||
Forfeited - number (in shares) | (25,000) | (134,750) | (64,750) |
Forfeited - Weighted average exercise price (in EUR per share) | € 3.05 | € 3.09 | € 3.30 |
Expired - number (in shares) | (285,088) | ||
Expired - Weighted average exercise price (in EUR per share) | € 3.99 | ||
Outstanding - number (in shares) | 1,347,600 | 1,207,600 | 1,427,438 |
Outstanding - Weighted average exercise price (in EUR per share) | € 2.61 | € 2.61 | € 2.94 |
Exercisable - number (in shares) | 772,600 | 598,850 | 774,938 |
Exercisable - Weighted average exercise price (in EUR per share) | € 2.44 | € 2.29 | € 2.87 |
Share purchase options available for grant - number (in shares) | 250,428 | 250,428 | 243,428 |
Note 16 - Shareholders' Equit_5
Note 16 - Shareholders' Equity - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (Details) | 12 Months Ended | |
Dec. 31, 2018EUR (€)€ / sharesshares | ||
Outstanding options - Number (in shares) | shares | 1,347,600 | |
Outstanding options - Weighted average remaining contractual life (Day) | 5 days | |
Outstanding options - Weighted average exercise price (in EUR per share) | € 2.61 | |
Outstanding options - Aggregate intrinsic value | € | [1] | |
Exercisable options - Number (in shares) | shares | 772,600 | [2] |
Exercisable options - Weighted average exercise price (in EUR per share) | € 2.44 | [2] |
Exercisable options - Aggregate intrinsic value | € | [1],[2] | |
Exercise price, Lower range (in EUR per share) | € 1.88 | |
Exercise price, Upper range (in EUR per share) | € 3.22 | |
Range 1 [Member] | ||
Outstanding options - Number (in shares) | shares | 505,000 | |
Outstanding options - Weighted average remaining contractual life (Day) | 7 days | |
Outstanding options - Weighted average exercise price (in EUR per share) | € 3.22 | |
Outstanding options - Aggregate intrinsic value | € | [1] | |
Exercisable options - Number (in shares) | shares | 252,500 | [2] |
Exercisable options - Weighted average exercise price (in EUR per share) | € 3.22 | [2] |
Exercisable options - Aggregate intrinsic value | € | [1],[2] | |
Range 2 [Member] | ||
Outstanding options - Number (in shares) | shares | 165,000 | |
Outstanding options - Weighted average remaining contractual life (Day) | 9 days | |
Outstanding options - Weighted average exercise price (in EUR per share) | € 2.65 | |
Outstanding options - Aggregate intrinsic value | € | [1] | |
Exercisable options - Number (in shares) | shares | [2] | |
Exercisable options - Weighted average exercise price (in EUR per share) | [2] | |
Exercisable options - Aggregate intrinsic value | € | [1],[2] | |
Range 3 [Member] | ||
Outstanding options - Number (in shares) | shares | 210,000 | |
Outstanding options - Weighted average remaining contractual life (Day) | 8 days | |
Outstanding options - Weighted average exercise price (in EUR per share) | € 2.39 | |
Outstanding options - Aggregate intrinsic value | € | [1] | |
Exercisable options - Number (in shares) | shares | 52,500 | [2] |
Exercisable options - Weighted average exercise price (in EUR per share) | € 2.39 | [2] |
Exercisable options - Aggregate intrinsic value | € | [1],[2] | |
Range 4 [member] | ||
Outstanding options - Number (in shares) | shares | 120,100 | |
Outstanding options - Weighted average remaining contractual life (Day) | 1 day | |
Outstanding options - Weighted average exercise price (in EUR per share) | € 2.38 | |
Outstanding options - Aggregate intrinsic value | € | [1] | |
Exercisable options - Number (in shares) | shares | 120,100 | [2] |
Exercisable options - Weighted average exercise price (in EUR per share) | € 2.38 | [2] |
Exercisable options - Aggregate intrinsic value | € | [1],[2] | |
Range 5 [Member] | ||
Outstanding options - Number (in shares) | shares | 297,500 | |
Outstanding options - Weighted average remaining contractual life (Day) | 4 days | |
Outstanding options - Weighted average exercise price (in EUR per share) | € 1.91 | |
Outstanding options - Aggregate intrinsic value | € | [1] | |
Exercisable options - Number (in shares) | shares | 2,975,000 | [2] |
Exercisable options - Weighted average exercise price (in EUR per share) | € 1.91 | [2] |
Exercisable options - Aggregate intrinsic value | € | [1],[2] | |
Range 6 [Member] | ||
Outstanding options - Number (in shares) | shares | 50,000 | |
Outstanding options - Weighted average remaining contractual life (Day) | 1 day | |
Outstanding options - Weighted average exercise price (in EUR per share) | € 1.88 | |
Outstanding options - Aggregate intrinsic value | € | [1] | |
Exercisable options - Number (in shares) | shares | 50,000 | [2] |
Exercisable options - Weighted average exercise price (in EUR per share) | € 1.88 | [2] |
Exercisable options - Aggregate intrinsic value | € | [1],[2] | |
[1] | The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company's closing stock price of $1.85 at December 31, 2018, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date. | |
[2] | Fully vested options are all exercisable options |
Note 16 - Shareholders' Equit_6
Note 16 - Shareholders' Equity - Non-vested Options Activity (Details) - € / shares | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Non-vested options outstanding (in shares) | 593,750 | ||
Non-vested options outstanding, weighted average grant-date fair value (in EUR per share) | € 1.53 | ||
Non-vested options granted (in shares) | 165,000 | ||
Non-vested options granted, weighted average grant-date fair value (in EUR per share) | € 1.33 | € 1.29 | € 1.67 |
Non-vested options vested (in shares) | (180,000) | ||
Non-vested options vested, weighted average grant-date fair value (in EUR per share) | € 1.56 | ||
Non-vested options forfeited (in shares) | (3,750) | ||
Non-vested options forfeited, weighted average grant-date fair value (in EUR per share) | € 1.29 | ||
Non-vested options outstanding (in shares) | 575,000 | 593,750 | |
Non-vested options outstanding, weighted average grant-date fair value (in EUR per share) | € 1.47 | € 1.53 |
Note 16 - Shareholders' Equit_7
Note 16 - Shareholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) Net of Tax (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Balance | € 25,158 | € 24,451 |
Balance | 24,964 | 25,158 |
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | ||
Balance | (3,027) | (3,315) |
Other comprehensive income (loss) before reclassifications | ||
Reclassified from accumulated other comprehensive loss | ||
Net current-period other comprehensive income (loss) | (146) | 288 |
Balance | (3,173) | (3,027) |
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] | ||
Balance | (577) | (634) |
Other comprehensive income (loss) before reclassifications | ||
Reclassified from accumulated other comprehensive loss | ||
Net current-period other comprehensive income (loss) | 57 | |
Balance | (577) | (577) |
AOCI Attributable to Parent [Member] | ||
Balance | (3,604) | (3,949) |
Other comprehensive income (loss) before reclassifications | ||
Reclassified from accumulated other comprehensive loss | ||
Net current-period other comprehensive income (loss) | (146) | 345 |
Balance | € (3,748) | € (3,604) |
Note 17 - Total Sales - Sales b
Note 17 - Total Sales - Sales by Geographical Area (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Revenues | € 39,163 | € 35,686 | € 35,579 |
Asia [Member] | |||
Revenues | 14,119 | 13,461 | 10,427 |
FRANCE | |||
Revenues | 11,577 | 10,573 | 9,606 |
UNITED STATES | |||
Revenues | 2,048 | 1,748 | 3,418 |
Other geographical Areas [Member] | |||
Revenues | € 11,419 | € 9,904 | € 12,127 |
Note 17 - Total Sales - Timing
Note 17 - Total Sales - Timing of Revenue Recognition (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Revenues | € 39,163 | € 35,686 | € 35,579 |
Transferred at Point in Time [Member] | |||
Revenues | 31,373 | 28,760 | 29,842 |
Transferred over Time [Member] | |||
Revenues | € 7,790 | € 6,927 | € 5,737 |
Note 18 - Other Revenues - Othe
Note 18 - Other Revenues - Other Revenues (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Revenues | € 39,183 | € 35,746 | € 35,611 |
Licenses and Others [Member] | |||
Revenues | 19 | 60 | 32 |
Product and Service, Other [Member] | |||
Revenues | € 19 | € 60 | € 32 |
Note 19 - Costs of Sales - Sche
Note 19 - Costs of Sales - Schedule of Costs of Sales (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Direct costs of sales | € (13,683) | € (12,706) | € (11,161) |
Indirect costs of sales | (8,583) | (8,232) | (8,039) |
Total costs of sales | € (22,266) | € (20,938) | € (19,200) |
Note 20 - Research and Develo_3
Note 20 - Research and Development Expenses - Research and Development Expenses (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Gross research and development expenses | € (4,863) | € (4,539) | € (4,577) |
Research Tax Credit | 685 | 504 | 511 |
Grants | 90 | 154 | 198 |
Net Research and development expenses | € (4,088) | € (3,881) | € (3,868) |
Note 21 - Financial Income, N_3
Note 21 - Financial Income, Net - Schedule of Financial Income (Expense) (Details) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | ||
Interest income | € 19 | € 18 | € 21 | |
Interest expense | (111) | (44) | (57) | |
Warrants exercised / forfeited | 889 | 625 | 174 | |
Changes in fair value of Financial Instrument (1) | [1] | 2,044 | 3,811 | |
Total | € 797 | € 2,643 | € 3,949 | |
[1] | For more details on the fair value of Financial Instruments, please refer to Notes 14-2 and 25. |
Note 22 - Income Taxes (Details
Note 22 - Income Taxes (Details Textual) € in Thousands, $ in Millions | 12 Months Ended | ||||
Dec. 31, 2022 | Dec. 31, 2018USD ($) | Dec. 31, 2018EUR (€) | Dec. 31, 2017EUR (€) | Dec. 31, 2016EUR (€) | |
Deferred Tax Assets, Operating Loss Carryforwards, Foreign | € 13,675 | ||||
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration | € 55,253 | ||||
U.S Subsidiary Taxable Net Income Subject to Lower Taxes with New Tax Law, Minimum | $ | $ 0.1 | ||||
Effective Income Tax Rate Reconciliation, at French Corporate Income Tax Rate, Percent | 33.33% | 33.33% | |||
Income Tax Examination, Penalties and Interest Expense, Total | € 0 | € 0 | € 0 | ||
Scenario, Forecast [Member] | |||||
Effective Income Tax Rate Reconciliation, at French Corporate Income Tax Rate, Percent | 25.00% | ||||
Foreign Tax Authority [Member] | |||||
Operating Loss Carryforwards, Total | € 57,595 | ||||
Foreign Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | |||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | 21.00% | |||
Foreign Tax Authority [Member] | Minimum [Member] | Internal Revenue Service (IRS) [Member] | |||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 15.00% | ||||
Foreign Tax Authority [Member] | Maximum [Member] | Internal Revenue Service (IRS) [Member] | |||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 39.00% | ||||
Foreign Tax Authority [Member] | EDAP TMS S.A. [Member] | |||||
Operating Loss Carryforwards, Total | € 32,535 | ||||
Foreign Tax Authority [Member] | EDAP Technomed Inc. [Member] | |||||
Operating Loss Carryforwards, Total | 21,229 | ||||
Foreign Tax Authority [Member] | Edap Technomed Co Ltd Japan [Member] | |||||
Operating Loss Carryforwards, Total | 2,342 | ||||
Foreign Tax Authority [Member] | EDAP Technomed Italia S.R.L. [Member] | |||||
Operating Loss Carryforwards, Total | € 1,489 |
Note 22 - Income Taxes - Income
Note 22 - Income Taxes - Income (Loss) Before Income Taxes (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income (Loss) from Continuing Operations before Income Taxes | € 20 | € (293) | € 4,444 |
FRANCE | |||
Income (Loss) from Continuing Operations before Income Taxes, Domestic | 1,687 | 1,003 | 4,936 |
Other Countries [Member] | |||
Income (Loss) from Continuing Operations before Income Taxes, Foreign | € (1,667) | € (1,296) | € (492) |
Note 22 - Income Taxes - Inco_2
Note 22 - Income Taxes - Income Tax Benefit (Expense) (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Current income tax benefit (expense) | € (515) | € (534) | € (572) |
Deferred income tax (expense) benefit | 157 | 146 | (32) |
Income tax (expense) credit | (358) | (388) | (602) |
FRANCE | |||
Current income tax benefit (expense) | (163) | (161) | (323) |
Deferred income tax (expense) benefit | 2 | (15) | (2) |
Other Countries [Member] | |||
Current income tax benefit (expense) | (351) | (373) | (249) |
Deferred income tax (expense) benefit | € 155 | € 161 | € (30) |
Note 22 - Income Taxes - Deferr
Note 22 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Net operating loss carry forwards | € 13,675 | € 13,218 |
Elimination of intercompany profit in inventory | 187 | 167 |
Elimination of intercompany profit in fixed assets | 343 | 265 |
Provisions for retirement indemnities | 488 | 566 |
Capital leases treated as operating leases for tax, asset | 10 | |
Capital leases treated as operating leases for tax, liability | (3) | |
Other items | 174 | 216 |
Total deferred tax assets | 14,877 | 14,431 |
Total deferred tax liabilities | ||
Net deferred tax assets | 14,877 | 14,431 |
Valuation allowance for deferred tax assets | (14,553) | (14,266) |
Deferred tax assets (liabilities), net of allowance | € 324 | € 165 |
Note 22 - Income Taxes - Effect
Note 22 - Income Taxes - Effective Tax Rate Reconciliation (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Effective income / (loss) tax at French statutory tax rate | € (6) | € 98 | € (1,480) |
Income of foreign subsidiaries taxed at different tax rates | (124) | 64 | 109 |
Effect of net operating loss carry-forwards and valuation allowances | (210) | (1,530) | 115 |
Non-taxable debt fair value variation | 235 | 1,026 | 1,207 |
Permanent differences | (392) | 178 | 217 |
Effect of cancellation of intra-group positions | 35 | 144 | |
French business tax included in income tax (CVAE) | (161) | (161) | (152) |
Other | 265 | (207) | (617) |
Effective income (loss) tax | € (358) | € (388) | € (602) |
Note 23 - Earnings (Loss) Per_3
Note 23 - Earnings (Loss) Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - EUR (€) € / shares in Units, € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income (loss) available to common shareholders (in Euros) | € (338,382) | € (681,345) | € 3,842,201 |
Number of shares for the computation of basic EPS (in shares) | 28,997,866 | 28,961,928 | 27,823,313 |
Basic EPS (in Euros) (in EUR per share) | € (0.01) | € (0.02) | € 0.14 |
Effect of dilutive securities (in shares) | 347,500 | 581,915 | 1,542,270 |
Number of shares for the computation of diluted EPS (in shares) | 28,997,866 | 28,961,928 | 29,365,583 |
Diluted EPS income / (loss) (in Euros) (in EUR per share) | € (0.01) | € (0.02) | € 0.13 |
Note 25 - Fair Value of Finan_3
Note 25 - Fair Value of Financial Instruments - Schedule of Fair Value Measurement Inputs Level 1 (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Assets: | ||||
Cash and cash equivalents | € 19,464 | € 20,004 | € 21,989 | € 13,578 |
Liabilities: | ||||
Short-term borrowings | 3,683 | 2,718 | ||
Long-Term Debt | 1,830 | 1,217 | ||
Fair Value, Inputs, Level 1 [Member] | ||||
Assets: | ||||
Cash and cash equivalents | 19,464 | 20,004 | ||
Liabilities: | ||||
Short-term borrowings | 3,683 | 2,718 | ||
Long-Term Debt | 1,830 | 1,217 | ||
Fair Value, Inputs, Level 3 [Member] | ||||
Liabilities: | ||||
Investor Warrants | € 840 |
Note 25 - Fair Value of Finan_4
Note 25 - Fair Value of Financial Instruments - Schedule of Fair Value Measurement Inputs Level 3 (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | ||
March 2012 Investor Warrants [member] | |||
Balance | € 640 | ||
Warrants forfeited (see note 21)(1) . | [1] | (489) | |
Warrants exercises (see note 21) (1) | [1] | (136) | |
FV adjustments (see note 21) (1) | [1] | ||
USD/EUR exchange impact(2) | [2] | (16) | |
Balance | |||
March 2012 Placement Agent Warrants [Member] | |||
Balance | 328 | 1,118 | |
Warrants forfeited (see note 21)(1) . | [1] | ||
Warrants exercises (see note 21) (1) | [1] | ||
FV adjustments (see note 21) (1) | [1] | (345) | (656) |
USD/EUR exchange impact(2) | [2] | 17 | (135) |
Balance | 328 | ||
May 2013 Investor Warrants [Member] | |||
Balance | 512 | 2,162 | |
Warrants forfeited (see note 21)(1) . | [1] | ||
Warrants exercises (see note 21) (1) | [1] | ||
FV adjustments (see note 21) (1) | [1] | (544) | (1,388) |
USD/EUR exchange impact(2) | [2] | 32 | (262) |
Balance | 512 | ||
May 2013 Placement Agent Warrants [Member] | |||
Balance | 840 | 3,921 | |
Warrants forfeited (see note 21)(1) . | [1] | (489) | |
Warrants exercises (see note 21) (1) | [1] | (136) | |
FV adjustments (see note 21) (1) | [1] | (889) | (2,044) |
USD/EUR exchange impact(2) | [2] | 49 | (412) |
Balance | € 840 | ||
[1] | Reported in the Consolidated Statement of Income in line "Financial (expenses) income net" | ||
[2] | Reported in the Consolidated Statement of Income in line "Foreign currency exchange gain (loss), net" |
Note 26 - Concentration of Cr_2
Note 26 - Concentration of Credit Risk (Details Textual) - EUR (€) € in Millions | Dec. 31, 2018 | Dec. 31, 2017 |
Allowance for Doubtful Accounts Receivable, Ending Balance | € 1.4 | € 1 |
Note 28 - Segment Information_2
Note 28 - Segment Information (Details Textual) | 12 Months Ended |
Dec. 31, 2018 | |
Number of Reportable Segments | 2 |
Note 28 - Segment Information -
Note 28 - Segment Information - Reconciliation of Operating Profit (Loss) From Segments to Consolidated (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Segment operating income (loss) | € (1,315) | € (2,027) | € 392 |
Financial income (expense), net | 797 | 2,643 | 3,949 |
Foreign Currency exchange (losses) gains, net | 538 | (909) | 103 |
Income tax (expense) credit | (358) | (388) | (602) |
Net income (loss) | € (338) | € (681) | € 3,842 |
Note 28 - Segment Information_3
Note 28 - Segment Information - Schedule of Segment Reporting Information By Segment (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Revenues | € 39,183 | € 35,746 | € 35,611 |
Cost of sales | (22,266) | (20,938) | (19,200) |
Gross profit | 16,917 | 14,808 | 16,411 |
Research and development expenses | (4,088) | (3,881) | (3,868) |
Selling and marketing expenses | (10,551) | (9,526) | (8,856) |
General and administrative expenses | (3,593) | (3,428) | (3,296) |
Segment operating income (loss) | (1,315) | (2,027) | 392 |
Total Assets | 48,740 | 46,897 | |
Goodwill | 2,412 | 2,412 | |
Product [Member] | |||
Revenues | 25,070 | 22,580 | 24,045 |
Cost of sales | (14,053) | (13,170) | (12,288) |
HIFU Treatments and Devices Leased [Member] | |||
Revenues | 5,086 | 5,095 | 4,906 |
Cost of sales | (2,557) | (2,667) | (2,527) |
Parts and Services [Member] | |||
Revenues | 9,007 | 8,011 | 6,628 |
Cost of sales | (5,655) | (5,101) | (4,385) |
Product and Services, Excluding Other [Member] | |||
Revenues | 39,163 | 35,686 | 35,579 |
Product and Service, Other [Member] | |||
Revenues | 19 | 60 | 32 |
High Intensity Focused Ultrasound (HIFU) [Member] | |||
Revenues | 11,044 | 9,513 | 13,819 |
Cost of sales | (5,312) | (4,732) | (5,710) |
Gross profit | 5,732 | 4,782 | 8,109 |
Research and development expenses | (2,394) | (2,469) | (2,452) |
Selling and marketing expenses | (4,628) | (4,004) | (3,888) |
General and administrative expenses | (1,036) | (1,009) | (804) |
Total expenses | (8,057) | (7,482) | (7,144) |
Segment operating income (loss) | (2,325) | (2,701) | 964 |
Total Assets | 13,648 | 11,333 | 11,680 |
Capital expenditures | 1,154 | 1,190 | 1,013 |
Long-lived assets | 2,855 | 2,804 | 1,775 |
Goodwill | 645 | 645 | 645 |
High Intensity Focused Ultrasound (HIFU) [Member] | Product [Member] | |||
Revenues | 5,494 | 4,232 | 9,382 |
High Intensity Focused Ultrasound (HIFU) [Member] | HIFU Treatments and Devices Leased [Member] | |||
Revenues | 3,750 | 3,800 | 3,547 |
High Intensity Focused Ultrasound (HIFU) [Member] | Parts and Services [Member] | |||
Revenues | 1,780 | 1,445 | 862 |
High Intensity Focused Ultrasound (HIFU) [Member] | Product and Services, Excluding Other [Member] | |||
Revenues | 11,025 | 9,477 | 13,791 |
High Intensity Focused Ultrasound (HIFU) [Member] | Product and Service, Other [Member] | |||
Revenues | 19 | 36 | 28 |
Urology Devices and Services (UDS) [Member] | |||
Revenues | 28,139 | 26,233 | 21,792 |
Cost of sales | (16,954) | (16,207) | (13,490) |
Gross profit | 11,185 | 10,026 | 8,302 |
Research and development expenses | (1,694) | (1,413) | (1,416) |
Selling and marketing expenses | (5,923) | (5,521) | (4,968) |
General and administrative expenses | (1,311) | (1,057) | (1,177) |
Total expenses | (8,928) | (7,991) | (7,560) |
Segment operating income (loss) | 2,257 | 2,035 | 742 |
Total Assets | 29,849 | 27,803 | 24,202 |
Capital expenditures | 775 | 928 | 608 |
Long-lived assets | 5,158 | 4,278 | 3,812 |
Goodwill | 1,767 | 1,767 | 1,767 |
Urology Devices and Services (UDS) [Member] | Product [Member] | |||
Revenues | 19,576 | 18,348 | 14,664 |
Urology Devices and Services (UDS) [Member] | HIFU Treatments and Devices Leased [Member] | |||
Revenues | 1,336 | 1,295 | 1,359 |
Urology Devices and Services (UDS) [Member] | Parts and Services [Member] | |||
Revenues | 7,227 | 6,566 | 5,766 |
Urology Devices and Services (UDS) [Member] | Product and Services, Excluding Other [Member] | |||
Revenues | 28,139 | 26,209 | 21,789 |
Urology Devices and Services (UDS) [Member] | Product and Service, Other [Member] | |||
Revenues | 24 | 4 | |
EDAP Technomed Co Ltd. [Member] | |||
Revenues | |||
Cost of sales | |||
Gross profit | |||
Research and development expenses | |||
Selling and marketing expenses | |||
General and administrative expenses | (1,246) | (1,362) | (1,315) |
Total expenses | (1,246) | (1,362) | (1,315) |
Segment operating income (loss) | (1,246) | (1,362) | (1,315) |
Total Assets | 5,243 | 7,761 | 10,709 |
Capital expenditures | |||
Long-lived assets | 192 | ||
Goodwill | |||
EDAP Technomed Co Ltd. [Member] | Product [Member] | |||
Revenues | |||
EDAP Technomed Co Ltd. [Member] | HIFU Treatments and Devices Leased [Member] | |||
Revenues | |||
EDAP Technomed Co Ltd. [Member] | Parts and Services [Member] | |||
Revenues | |||
EDAP Technomed Co Ltd. [Member] | Product and Services, Excluding Other [Member] | |||
Revenues | |||
EDAP Technomed Co Ltd. [Member] | Product and Service, Other [Member] | |||
Revenues | |||
FDA [Member] | |||
Revenues | 39,183 | 35,746 | 35,611 |
Cost of sales | (22,266) | (20,938) | (19,200) |
Gross profit | 16,917 | 14,808 | 16,411 |
Research and development expenses | (4,088) | (3,881) | (3,868) |
Selling and marketing expenses | (10,551) | (9,526) | (8,856) |
General and administrative expenses | (3,593) | (3,428) | (3,296) |
Total expenses | (18,232) | (16,835) | (16,019) |
Segment operating income (loss) | (1,315) | (2,027) | 392 |
Total Assets | 48,740 | 46,897 | 46,591 |
Capital expenditures | 1,928 | 2,118 | 1,621 |
Long-lived assets | 8,013 | 7,082 | 5,779 |
Goodwill | 2,412 | 2,412 | 2,412 |
FDA [Member] | Product [Member] | |||
Revenues | 25,070 | 22,580 | 24,045 |
FDA [Member] | HIFU Treatments and Devices Leased [Member] | |||
Revenues | 5,086 | 5,095 | 4,906 |
FDA [Member] | Parts and Services [Member] | |||
Revenues | 9,007 | 8,011 | 6,628 |
FDA [Member] | Product and Services, Excluding Other [Member] | |||
Revenues | 39,163 | 35,686 | 35,579 |
FDA [Member] | Product and Service, Other [Member] | |||
Revenues | € 19 | € 60 | € 32 |
Note 29 - Valuation Accounts -
Note 29 - Valuation Accounts - Schedule of Valuation Accounts (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] | |||
Balance | € 14,266 | € 19,450 | € 19,212 |
Charges to costs and expenses | 515 | 1,536 | 238 |
Deductions: write-off and others | (228) | (6,720) | |
Balance | 14,553 | 14,266 | 19,450 |
SEC Schedule, 12-09, Allowance, Credit Loss [Member] | |||
Balance | 1,029 | 960 | 1,091 |
Charges to costs and expenses | 365 | 69 | 103 |
Deductions: write-off and others | 10 | (233) | |
Balance | 1,404 | 1,029 | 960 |
SEC Schedule, 12-09, Reserve, Inventory [Member] | |||
Balance | 723 | 803 | 728 |
Charges to costs and expenses | 355 | 239 | 121 |
Deductions: write-off and others | (104) | (319) | (46) |
Balance | 974 | 723 | 803 |
SEC Schedule, 12-09, Reserve, Warranty [Member] | |||
Balance | 449 | 548 | 576 |
Charges to costs and expenses | 433 | 316 | 319 |
Deductions: write-off and others | (334) | (415) | (347) |
Balance | € 548 | € 449 | € 548 |
Note30 - Supplemental Disclosur
Note30 - Supplemental Disclosures of Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income taxes paid (refunds received) | € 407 | € 585 | € 596 |
Interest paid | 49 | 41 | 41 |
Interest received | 12 | 7 | 4 |
Capital lease obligations incurred | € 427 | € 484 | € 285 |
Note 31 - Related Party Trans_2
Note 31 - Related Party Transactions (Details Textual) € in Thousands | 12 Months Ended | ||||
Dec. 31, 2017EUR (€) | Dec. 31, 2016EUR (€) | Dec. 31, 2018MYR (RM) | Dec. 31, 2018EUR (€) | Dec. 31, 2018JPY (¥) | |
Related Parties Amount in Cost of Sales | € 41 | € 62 | |||
Due to Related Parties, Current, Total | 0 | € 0 | |||
Revenue from Related Parties | 161 | € 483 | |||
Accounts Receivable, Related Parties, Current | € 0 | € 0 | |||
EDAP Technomed Co Ltd. [Member] | JAPAN | Loans Payable [Member] | |||||
Debt Instrument, Face Amount | ¥ | ¥ 80,000,000 | ||||
EDAP Technomed Sdn Bdh [Member] | Malaysia 1 [Member] | Loans Payable [Member] | |||||
Debt Instrument, Face Amount | RM | RM 90,000 |